Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
02/2008 | Recent  |  08: Dec | Nov | Oct | Sp | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 07: D | N | O | S | A | J | J | M | A | M | F | J |  | 06: 12 | 11 | 10 | 09 | 8 | 7 | 6 | 5 | 4 | Dec | Nov |  | 2010 | 2009 |

Drug, bio-affecting and body treating compositions February patents and inventions 02/08

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
02/28/2008 > patent applications in patent subcategories. patents and inventions

20080051315 - Grp receptor-related methods for the treating and preventing fear-related disorders: This invention provides a method for treating a subject afflicted with a fear-related disorder comprising administering to the subject a therapeutically effective amount of a gastrin-releasing peptide receptor agonist. This invention further provides a method for inhibiting in a subject the onset of a fear-related disorder resulting from exposure to... Agent: Cooper & Dunham, LLP

20080051319 - Inhibiting jnk signaling promotes cns axon regeneration: Regeneration of a lesioned CNS axon of mature neuron, determined to be subject to regeneration inhibition by endogenous cJun-N-terminal kinase (JNK), is promoted by contacting the neuron with an exogenous JNK inhibitor at a concentration sufficient to partially inhibit the JNK, and thereby promote a resultant regeneration of the axon.... Agent: Richard Aron Osman

20080051323 - Chloroquine drug compositions and methods for their synthesis: The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include... Agent: Kenneth M. Kosak

20080051325 - Oligopeptide: The object of the present invention is to provide an oligopeptide having hair growth promoting activity. The present invention provides an oligopeptide which is represented by the formula (I): X1-X2-X3-X4-X5-X6-X7, or the like wherein X1 represents an amino acid residue such as Ser, X2 represents an amino acid residue such... Agent: Morrison & Foerster LLP

20080051327 - Crystals of an aurora-a tpx2 complex, tpx2 binding site of aurora-a, aurora-a ligands and their use: The present invention relates to crystals of phosphorylated Aurora-A kinase fragment alone and in complex with a ligand, amino acid residues 1-43 of human TPX2. This invention also relates to methods for designing and selecting ligands, in particular allosteric inhibitors of Aurora-A, that bind to the Aurora-A kinase and their... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080051329 - Fsh and fsh variant formulations, products and methods: This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080051330 - Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses: Novel compositions and methods of treating and preventing a viral infection are provided. A method of blocking a viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which involves administering to a subject suffering or about to suffer from a viral infection a therapeutically effective amount of a... Agent: Don D. Cha

20080051332 - Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone: A method for modulating hematopoietic stem cells and treating a hematologic disease in a mammal comprising administering intranasally a therapeutically effective amount of a PTH formulation. The PTH formulation may contain teriparatide.... Agent: Nastech Pharmaceutical Company Inc

20080051350 - Therapeutic use for a group of sulphated polysaccharides: The present invention relates to the use of a sulphated polysaccharide in acid form or as a physiologically acceptable salt thereof, selected from the group consisting of inulin sulphate, gellan sulphate, pullulan sulphate, curdlan sulphate, alginiq acid sulphate, laminarin sulphate, and pectin sulphate, for the preparation of a medicament for... Agent: Venable LLP

20080051352 - Novel process for the preparation of telithromycin: e

20080051354 - Human schwannoma cell line: In a preferred embodiment, the present invention relates to a Schwannoma cell line derived from a Schwann tumor in a patient with Neurofibromatosis type 2 (NF2) and immortalized with HPV E6-E7 genes. The cell line has a unique splice site mutation of the NF2 gene. The immortalized cell line is... Agent: Knobbe Martens Olson & Bear LLP

20080051355 - System for obfuscating identity: Compositions, apparatus, systems, kits, and methods for obfuscating the nucleic acid and/or protein content of an environment.... Agent: Searete LLC Clarence T. Tegreene

20080051364 - Therapeutic treatment of accelerated bone resorption: m

20080051365 - Treatment of inflammation: The present invention concerns the therapeutic treatment of inflammatory conditions by a combined administration of methotrexate and an agonist of the A3 adenosine receptor. Provided are methods of therapeutic treatment comprising such a combined administration, pharmaceutical compositions useful in such methods comprising either an and use if either an agonist... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080051367 - Hyaluronan used in improvement of anti-oxidation and proliferation in chondrocytes: The present invention relates to the use of hyaluronan in protecting chondrocytes against oxidative damages and further promoting their proliferation. Particularly, the present invention relates to the use of hyaluronan with a molecular weight of 600,000-1,200,000 Dalton in protecting chondrocytes against reactive oxygen damages and further promoting their proliferation.... Agent: Troxell Law Office PLLC

20080051316 - Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment: Methods of treating a mammal at risk for ischemia-reperfusion injury are provided. The methods comprise administering an adrenomedullin binding protein-1 (AMBP-1) to the mammal in sufficient amount to reduce the injury. Also provided are methods of treating a mammal at risk for ischemia-reperfusion injury to the bowel. The methods comprise... Agent: Amster, Rothstein & Ebenstein LLP

20080051318 - Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with Alzheimer's Disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods... Agent: Celera, An Applera Business Unit

20080051317 - Polypeptides comprising unnatural amino acids, methods for their production and uses therefor: Certain aspects of the present invention provide artificial polypeptides containing one or more unnatural amino acids and methods for producing and using the artificial polypeptides.... Agent: Wolf Greenfield & Sacks, P.C.

20080051320 - S-nitrosoprotein preparation and production method therefor: A protein is efficiently nitrosylated with nitrogen monoxide by merely mixing S-nitrosoglutathione as a nitrogen monoxide donor with a protein solution containing a stabilizing agent comprising at least one compound or a combination of plural compounds selected from an N-acetylamino acid, a fatty acid, and a fatty acid salt. The... Agent: Kubovcik & Kubovcik

20080051321 - Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity: Disclosed is the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, R1, R2, R3, R4, R5, X, Alk1, Alk2, Ar1, and Ar2 are as defined in the specification. These compounds, as selective agonists activating peroxisome proliferator-activated receptors (PPAR), in particularly the... Agent: Patrick H. Higgins Mathews, Collins, Shepherd & Mckay

20080051322 - 14400, 2838, 14618, 15334, 14274, 32164, 39404, 38911, 26904, 31237, 18057, 16405, 32705, 23224, 27423, 32700, 32712 and 12216, novel seven-transmembrane proteins/g-protein coupled receptors: The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders. The invention further... Agent: Millennium Pharmaceuticals, Inc.

20080051324 - Medium-chain length fatty alcohols as stimulators of hematopoiesis: Medium-chain length fatty alcohols such as octanol, decanol, dodecanol, or analogues thereof can be used as a stimulator of hematopoiesis, hematopoietic stem cell proliferation, and/or proliferation of one or more of the progenitors of red or white blood cells (e.g., erythrocyte, leukocyte, neutrophil, granulocyte, megakaryocyte, or any combination thereof). It... Agent: Nixon & Vanderhye, PC

20080051326 - Antiinfective lipopeptides: The present invention relates to novel depsipeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel depsipeptide compounds and intermediates used in producing these compounds.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080051338 - 98 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080051334 - Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases: The present invention provides a novel protein encoded by the KCNC1 gene and discloses the differential expression of the gene KCNC1 coding for KCNC1 proteins in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating Alzheimer's disease in a... Agent: Venable LLP

20080051333 - Human alpha-defensins inhibit interleukin-1beta release: Human α-defensins are inhibitors of interleukin-1β post transitional processing and release. Interleukin-1β is a key cytokine involved in the initiation and amplification of the inflammatory process, including the inflammation of diseases such as Crohn's Disease and Ulcerative Colitis. Particularly, human neutrophil defensin-1(HNP-1) produced mainly by neutrophils, and human α-defensin 5(HD-5)... Agent: Aaron T. Olejniczak Andrus, Sceales, Starke & Sawall, LLP

20080051341 - Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or metabolic syndrome: A substance including the chemical structures of bicyclo[3.2.1]octan or the chemical structures of kaurene for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The unique chemical structures of bicyclo[3.2.1]octan alone or in... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080051343 - Method for fostering bone formation and preservation: A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any... Agent: Ostrolenk Faber Gerb & Soffen

20080051337 - Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease: The methodologies of the present invention demonstrate that a critical balance between pro- and anti-amyloidogenic molecules exists that regulates amyloid formation and cell death in Alzheimer's disease and Parkinson's disease. β-Synuclein, the non-amyloidogenic homologue of α-synuclein, is a negative modulator of α-synuclein and Aβ aggregation, having neuroprotective properties against α-synuclein... Agent: Morrison & Foerster LLP

20080051335 - Methods, compositions and devices for treating lesioned sites using bioabsorbable carriers: Methods and compositions for the sustained release of treatment agents to treat an occluded blood vessel and affected tissue and/or organs are disclosed. Porous or non-porous bioabsorbable glass, metal or ceramic bead, rod or fiber particles can be loaded with a treatment agent, and optionally an image-enhancing agent, and coated... Agent: Blakely Sokoloff Taylor & Zafman

20080051339 - Modulators of pharmacological agents: The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves,... Agent: King & Spalding LLP

20080051328 - Novel muscle growth regulator: A muscle growth regulating factor includes polynucleotide and polypeptide sequences, promoter sequences, constructs comprising the sequences, and compositions for regulating muscle growth and treating diseases associated with muscle growth. The present sequences can be used in identifying animals with altered muscle mass, and for selective breeding programs to produce animals... Agent: Knobbe Martens Olson & Bear LLP

20080051345 - Pharmaceutical compositions comprising fragments and homologs of troponin subunits: The present invention relates to pharmaceutical compositions comprising therapeutically effective amounts of troponin C, I or T subunits, fragments or homologs for the treatment of diseases or disorders involving abnormal angiogenesis and methods of use thereof.... Agent: David S. Resnick

20080051336 - Relaxin-3 chimeric polypeptides and their preparation and use: Chimeric polypeptides of relaxin-3, prepropolypeptides thereof, polynucleotides encoding such polypeptides, and associated expression vectors and host cells are described. The polypeptides may be used to prepare receptor-ligand complexes with GPCR135 or GPCR142, which may be used in assay methods.... Agent: Philip S. Johnson Johnson & Johnson

20080051342 - Trps1-mediated modulation of hair growth: The present invention provides for methods of inhibiting hair growth, comprising decreasing the level of TRPS1 mRNA and/or protein in hair follicle cells of a subject. The present invention also provides for methods of promoting hair growth, comprising increasing the level of TRPS1 mRNA and/or protein in hair follicle cells... Agent: Baker Botts L.L.P.

20080051340 - Use of proteins and peptides of the tgf-beta superfamily for purification and therapeutic methods: Members of the TGF-β superfamily and peptide fragments based on member proteins are employed to purify solutions containing member proteins or as therapeutics.... Agent: Wyeth/finnegan Henderson, LLP

20080051344 - Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof: The present invention relates to a novel isolated whitefly ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the whitefly ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation... Agent: Sughrue Mion, PLLC

20080051346 - Compounds and methods for modulating cell-adhesion mediated drug resistance: e

20080051347 - Tumour-associated peptides binding to mhc-molecules: The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080051349 - Peptide antagonists of zonulin and methods for use of the same: Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions.... Agent: Connolly Bove Lodge Hutz, LLP (for Alba Therapeutics)

20080051348 - Treatment of infections and other disorders: A method of treatment for treating, inhibiting, reducing or at least partly preventing respiratory or pulmonary microbial infection or gastrointestinal disorder of tissue of a subject, includes administering to a subject an effective amount of a composition including a polypeptide including thymosin β4 (TB4), an isoform of TB4, an N-terminal... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080051351 - Substances, compositions, and methods for treating alopecia: Substances, compositions and methods for hair treatment based on ultra-low molecular weight hyaluronic acid oligomers, possibly combined with trichogenic substances, useful for preventing hair loss and favouring its regrowth in subjects affected by androgenetic alopecia, alopecia areata, alopecia mucinosa and related disorders.... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20080051353 - Avermectin and avermectin monosaccharide substituted in the 4\"- and 4\" position respectively: A compound of the formula (I) wherein the bond between carbon atoms 22 and 23 indicated with a broken line is a single or double bond, m is 0 or 1, R1 represents a C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl group, R2 represents a hydrocarbyl group or a substituted hydrocarbyl group, and... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080051359 - Antisense oligonucleotide modulation of stat3 expression: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and... Agent: Eli Lilly & Company

20080051362 - Antisense therapy for hormone-regulated tumors: A method is provided for treating hormone-regulated tumors (for example, breast and prostatic tumors) in mammals, including humans, by administration of an antisense ODN which is complementary to a portion of the gene encoding IGFBP-5. Using the Shionogi tumor model in vitro and in vivo, the administration of such an... Agent: Marina Larson & Associates, LLC

20080051357 - Composition for attenuating neuropathic pain comprising a recombinant ventor expressing gad65: Provided is a pharmaceutical composition for attenuation of neuropathic pain comprising a GAD65-expressing recombinant vector. Direct introduction of the pharmaceutical composition of the present invention into a sciatic nerve leads to immediate therapeutic effects on peripheral neuropathic pain with a sustained and constant duration for several months. Therefore, the composition... Agent: Squire, Sanders & Dempsey L.l.p

20080051363 - G-rich polynucleotides as a novel therapeutic for the treatment of huntington's disease: The present invention relates to oligonucleotide compositions and therapeutic uses thereof to modify protein-protein interactions. In particular, the invention relates to the use of a guanidine-rich oligonucleotides to disrupt disease-causing protein aggregates, for example, Huntington's Disease (HD) protein aggregates... Agent: Mccarter & English, LLP Basil S. Krikelis

20080051358 - Novel human lysosomal protein and methods of its use: The gene associated and causative of classical late infantile neuronal ceroid lipofuscinosis (LINCL), CLN2, has been identified and characterized. The translation product of this gene is a novel protease and a deficiency in this activity results in LINCL. Identification of CLN2 will not only aid in the prevention of LINCL... Agent: Klauber & Jackson

20080051360 - Pkc ligands and polynucleotides encoding pkc ligands: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate PKC activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal, epitope... Agent: Sughrue Mion, PLLC

20080051361 - Rnai-mediated inhibition of gremlin for treatment of iop-related conditions: RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.... Agent: Alcon

20080051356 - Truncated 24kda basic fibroblast growth factor: The invention relates to fragments of an amino acid sequence of mature, full length 24 kDa fibroblast growth factor-2 or an analog thereof. The fragments have an activity that inhibits the migration of cultured cells as well as inhibiting angiogenesis, tumor growth, or any other processes that involve the migration... Agent: T. D. Foster

20080051366 - Aminosugar, glycosaminoglycan, and s-adenoslymethionine composition for the treatment and repair of connective tissue: A composition for the protection, treatment and repair and for reducing the inflammation of connective tissue in mammals and a method for the treatment of connective tissue in mammals by the administration of the composition. The composition includes S-Adenosylmethionine (SAM), and a component selected from an aminosugar or salts thereof... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080051368 - Process for the isolation and stabilization of low-molecular weight aminoglycans form waste egg shells: wherein M may be at one or more instances Na, Ca, K, Mg: and n is an integer between 20 and 40: (a) pre-preparation of the waste egg-shells for extraction of the embryonic low molecular weight aminoglycan compound of formula I using a polar organic solvent in water; (b) extraction... Agent: Bomi Patel-framroze

20080051369 - Skin cosmetic material: e

20080051370 - Ruthenium complexes for treating cancers: The invention concerns uses or methods for treating proliferative pathologies, in particular cancers, using ruthenium compounds and compositions containing the same. The invention also concerns novel ruthenium compounds, as well as their preparation method.... Agent: Nixon & Vanderhye, PC

20080051371 - Creatine phosphate analog prodrugs, compositions and uses thereof: Membrane permeable prodrugs of creatine phosphate analogs, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate analogs, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate analogs, or pharmaceutical compositions thereof are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080051372 - Methods utilizing cell-signaling lysophospholipids: The invention relates to methods of modulating neurite outgrowth, in culture or in a subject. The methods generally utilize cell-signaling phospholipids which interact and bind to the G protein-coupled cellular receptors (GPCRs). Such phospholipids include lysophospholipids, as well as synthetic lysophospholipid receptor agonists and antagonists that may be chemically distinct... Agent: Michael Best & Friedrich LLP

20080051373 - Parenteral preparations of gi-safer phospholipid-associated anti-inflammatories and methods of preparation and use: Parenteral preparations of phospholipid-associated anti-inflammatories (PL-AIs) are described to treat pain/inflammation, with reduced gastrointestinal (GI) toxicity. The PL-AIs can be composed of phosphatidylcholine (“PC”) associated with non-steroidal anti-inflammatory drugs (“NSAIDs”). To prepare the PL-AIs, a phospholipid is mixed with an NSAID in a polar solvent, solvent is removed, suspended in... Agent: Jackson Walker LLP

20080051374 - Therapeutic amides and related compounds: r

20080051375 - Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same: Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a vitamin D compound in combination with at least one additional therapeutic agent, such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising vitamin D compounds and at least... Agent: Jones Day

20080051376 - Method for producing albumin-corticoid conjugates: The invention relates to corticoid/transport protein conjugates, methods for the production thereof, and the use of the same in medicine, especially for the treatment of tumours and inflammatory processes, and for immunosuppression.... Agent: Morris Manning Martin LLP

20080051377 - Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof: The present invention is directed to monophasic pharmaceutical compositions comprising a conjugated estrogen and a hydrophilic or lipophilic excipient. The present invention is also directed to kits and applicators comprising the pharmaceutical compositions. The invention is also directed to methods for treating menopausal conditions in a female comprising administration of... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080051378 - Combinations comprising antimuscarinic agents and corticosteroids: e

20080051379 - Compositions and methods for the treatment of peripheral b-cell neoplasms: The present invention is directed to the use of a PDE4 inhibitor and a glucocorticoid to treat peripheral B-cell neoplasms. In particular, the present invention provides a method of treating individuals (e.g. patients) diagnosed with peripheral B-cell leukemias by administering pharmaceutical compositions comprising Type 4 cyclic adenosine monophosphate phosphodiesterase inhibitors... Agent: Ronald I. Eisenstein

20080051380 - Methods and compositions for treating cancer: Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C17,20-lyase inhibitor, such as abiraterone acetate (i.e., 3β-acetoxy-17-(3-pyridyl)androsta-5,16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising a... Agent: Jones Day

20080051381 - Suppression of estrus in mares by a single injection method: The present invention generally relates to methods of suppressing estrus in breeding or competitive animals comprising parenterally administering to breeding animals an estrus suppressing amount of 17-α-Allyl-17-β-hydroxyoestra-4,9,11-trien-3-one. According to the method of the present invention, estrus can be suppressed for any of a variety of periods including 30 days or... Agent: Roetzel & Andress

20080051382 - Crystalline forms of 3-beta-amino 17-methylene androstane-6-alpha 7-beta-diol hydrochloride: The invention relates to novel crystalline forms of 3-beta-amino-17-methylene-androstane-6-alpha,7-beta-diol hydrochloride, referred to as form A, form B and form C, a method for preparing same, the use thereof as a drug, and pharmaceutical compositions containing same.... Agent: Seed Intellectual Property Law Group PLLC

20080051383 - Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed... Agent: Myers Bigel Sibley & Sajovec

20080051384 - Antiviral agents: Disclosed are compounds and compositions of Formula (I) and their uses for treating Flaviviridae family virus infections.... Agent: Foley & Lardner LLP

20080051385 - Ocular allergy treatments: Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof.... Agent: Philip S. Johnson Johnson & Johnson

20080051387 - Tetrahydropyrido[3,4-d]pyrimidines and related analogues: in which variables are as described herein, as are methods for their preparation and use. Such compounds may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are partially useful in the treatment of a variety of disorders in humans, domesticated companion... Agent: Edward Angell Palmer & Dodge, LLP Client: Neurogen Corporation

20080051386 - Tricyclic pyrazole derivatives as cannabinoid receptor modulators:

20080051388 - Novel compounds that inhibit factor xa activity:

20080051389 - Small molecule apoptosis promoters: The invention provides small molecule mimics of the Smac peptide that are dimer- or dimer-like compounds having two amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and... Agent: Morrison & Foerster LLP

20080051391 - Fungicidal agent combinations: e

20080051390 - Imidazole amines as inhibitors of beta-secretase: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated β-amyloid deposits or β-amyloid levels in a patient.... Agent: Wyeth Patent Law Group

20080051392 - Pharmaceutical combinations for the treatment of respiratory diseases: e

20080051394 - 6h-oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands: in which R1, R2, R3 and R4 are as defined in Claim 1, are ligands of the nicotinic acetylcholine receptor and/or serotonergic ligands and are suitable for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease,... Agent: Millen, White, Zelano & Branigan, P.C.

20080051393 - Novel cannabinoids and methods of use: Water- and lipid-soluble cannabinoid compounds that are agonists for CB1 and CB2 receptors are provided. The cannabinoid compounds are useful for the treatment of retinal neurodegenerative disorders such as glaucoma, diabetic retinopathy and macular degeneration.... Agent: Wilmerhale/dc

20080051395 - 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors: The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080051396 - Costunolide derivatives: e

20080051397 - Benzothiazole formulations and use thereof: The present invention is related to macrogol glyceride pharmaceutical formulations containing benzothiazole derivatives. In particular, the invention is related to benzothiazole stearoyl macrogol pharmaceutical formulations, method of preparation and use thereof.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080051398 - Method of treating brain cancer: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to the use of these compounds... Agent: Myriad Genetics Inc. Intellecutal Property Department

20080051399 - Hydroxylated and methoxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors: s

20080051400 - Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound: The present invention relates to methods useful for treating or preventing anemia or thrombocytopenia, comprising administrating an effective amount of a Triheterocyclic Compound to a subject in need thereof. The present invention also relates to methods useful for preventing anemia or thrombocytopenia in a subject, comprising administrating an effective amount... Agent: Wilson Sonsini Goodrich & Rosati

20080051401 - 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer: The invention concerns pyrimidine derivatives of Formula (I) wherein each of p, R1, R2, q, R3, r, R4, X1 and Q1 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in... Agent: Morgan Lewis & Bockius LLP

20080051402 - Method of inhibiting c-kit kinase: e

20080051403 - Treatment for alzheimer's disease and related conditions: This invention provides the combination of a growth hormone secretagogue and a p38 kinase inhibitor for use in treatment or prevention of a disease associated with deposition of Aβ in the brain.... Agent: Merck And Co., Inc

20080051404 - Heteroaryl compounds useful as inhibitors of e1 activating enzymes: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.... Agent: Millennium Pharmaceuticals, Inc.

20080051405 - Therapeutic agents: The present invention provides compounds of formula I, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, type II diabetes, Metabolic syndrome and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease,... Agent: Pepper Hamilton LLP

20080051406 - Brimonidine and timolol compositions: Disclosed herein are compositions containing brimonidine and timolol. Therapeutic methods and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20080051407 - Antitumoral analogs of et-743: Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or derivatised aminomethylene group or an optionally protected or derivatised hydroxymethylene... Agent: Fish & Richardson PC

20080051408 - Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders: The invention relates to the use of PDE5 inhibitors, preferably sildenafil or tadalafil, optionally in combination with a further active ingredient, for treating and/or preventing hypopigmentary disorders.... Agent: Pearl Cohen Zedek Latzer, LLP

20080051409 - Indolizine carboxamides and aza and diaza derivatives thereof: e

20080051410 - Protein kinase targeted therapeutics: The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream... Agent: Casimir Jones, S.c.

20080051411 - Salts of fenofibric acid and pharmaceutical formulations thereof: In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In... Agent: Robert Deberardine Abbott Laboratories

20080051412 - Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses: The present invention provides stereoisomers and stereoisomeric mixtures of 3-aminocarbonyl-bicycloheptene-2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080051413 - Nitrophenylpiperazine derivative of xanthine which relaxes tracheal airway and increases respiratory performance: The effects of KMUP-3, (7-[2-[4-(4-Nitrobezene)peperazinyl]ethyl]-1,3-dimethylxanthine) on tracheal smooth muscle are provided. Intratracheal instillation of KMUP-3 avoids bronchoconstriction, decreases of lung resistance, and increases of dynamic lung compliance. These merits provide insightful benefits for the treatment in asthma and COPD (chronic obstructive pulmonary disease).... Agent: Trojan Law Offices

20080051414 - Protein kinase inhibitors: e

20080051415 - Novel piperazines, pharmaceutical compositions and methods of use thereof: Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080051416 - Novel compounds: s

20080051417 - Uses of selective cyclooxygenase-1 inhibitors: The present invention discloses effect of non-selective COX1 inhibitor such as aspirin, statins, thiazolidinediones or combinations thereof on COX2. Also disclosed herein is a method to avoid the adverse effects that the non-selective COX1 inhibitor may have when administered with statins and/or thiazolidinediones.... Agent: Benjamin Aaron Adler Adler & Associates

20080051418 - Arylalkanoic acid derivative: e

20080051419 - Amine derivatives useful as anticancer agents: and to pharmaceutically acceptable salts and solvates thereof, wherein X, Z, D, E, V, W, Y, R1, R2, R5, R6, L, and u are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I to a patient... Agent: Pfizer Inc

20080051420 - New compounds 317: d

20080051421 - Pyrazolo-pyridine: wherein A, D, E, L, M, Q, R1, R2 and R3 are as defined hereinabove. The present invention also relates to a process for their preparation, a pharmaceutical composition containing said derivatives and a method of treating or preventing acute or chronic neurological disorder comprising administering to a patient in... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080051422 - 4-aminoquinazoline derivatives and methods of use thereof: This invention relates to novel 4-aminoquinazolines, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of the EGFR and... Agent: Edwards Angell Palmer & Dodge LLP

20080051423 - Nitrogen heterocycle biaryls for osteoporosis and other diseases: i

20080051424 - Heterocyclyl-substituted nonadepsipeptides: The invention relates to nonadepsipeptides and methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.... Agent: Morrison & Foerster LLP

20080051425 - Vinorelbine derivatives: The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.... Agent: Nixon Peabody LLP - Patent Group

20080051426 - Indoloquinoline compounds as calcium channel blockers: Various calcium channel blockers and pharmaceutical compositions containing these compounds are disclosed. Calcium channel blockers are compounds capable of inhibiting calcium ion channels. Methods for preparing calcium channel blockers and their use as calcium channel antagonists are also disclosed.... Agent: Manfred E. Wolff

20080051427 - Pharmaceutical compositions and methods of using same: A pharmaceutical composition is provided that comprises a solid dispersion of implitapide. Such solid dispersions may include implitapide and least one pharmaceutically acceptable excipient. In some embodiments, the disclosed solid dispersions comprise substantially amorphous implitapide.... Agent: Goodwin Procter LLP Patent Administrator

20080051428 - Pyrroloquinoline quinone drugs and methods of use thereof: The invention includes compositions comprising substantially purified pyrroloquinoline quinone, that are useful in methods for the treatment and prevention of cardiac injury caused by hypoxia or ischemia. The invention also includes methods for the treatment and prevention of cardiac injury comprising contacting a composition of the invention with a human... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080051429 - Use of 4-amino-piperidines for treating sleep disorders: Inverse agonists and antagonists of serotonin receptors are disclosed for use in treating sleep disorders such as insomnia, and specifically sleep maintenance insomnia. The compound increase slow wave sleep, decrease the number of awakenings after sleep onset, and decrease the time awake after sleep onset.... Agent: Knobbe Martens Olson & Bear LLP

20080051430 - Acylated piperidine derivatives as melanocortin 4-receptor agonists: Certain novel N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction,... Agent: Merck And Co., Inc

20080051431 - Methods and compositions using immunomodulatory compounds in combination therapy: Provided herein are compositions comprising one or more immunomodulatory compounds and valproic acid, hydroxyurea or trichostatin A, methods for their use in CD34+ hematopoietic stem cell expansion in vitro and in vivo for bone marrow reconstitution and bone marrow transplantation, increasing fetal hemoglobin expression, and methods for treating, preventing and/or... Agent: Jones Day

20080051432 - Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors: wherein n represents 1, 2, 3, 4, 5 or 6; R1 represents from one to four of the same or different substituents selected from F, Cl, Br, C1-4 alkyl, OH, OC1-4 alkyl, NO2, NHC(O)C1-4 alkyl, NH2, NH(C1-4 alkyl), N(C1-4 alkyl)2; R2 represents OR3, NR3R4, N(R3)COR4, O2CR5; R3 and R4 represent... Agent: Matthias Scholl

20080051433 - Pyrrole-3-carboxamide derivatives for the treatment of obesity: The present invention relates to compounds of Formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.... Agent: Morgan Lewis & Bockius LLP

20080051435 - Crystalline and amorphous forms of tiagabine: The present invention provides 24 new forms of tiagabine, including 22 new crystalline forms of tiagabine and its salts, an amorphous form of tiagabine free base, and a cocrystal form of tiagabine hydrochloride with 2-furancarboxylic acid. The present invention further provides a process for preparing each of the new tiagabine... Agent: Cephalon, Inc.

20080051434 - Hemiasterlin derivatives and uses thereof in the treatment of cancer: e

20080051436 - Use of acylaminothiazole derivatives as therapeutic agents: Wherein R1, R2, R′2, R3, R4 and R5 are as described herein. Specifically, the compounds of the present invention exhibit an inhibitory effect on the production of β-amyloid peptide (β-A4) by inhibition of gamma protease. Therefore, the compounds of the present invention are useful in the treatment of pathologies such... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080051437 - Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation: The present invention provides methods of improving cognitive and motor deficits associated with central nervous system (CNS) disorder or condition in an animal. The methods comprise a general administration of phosphodiesterase 4 inhibitors and optionally training the animal under conditions sufficient to produce an improvement in performance.... Agent: Heller Ehrman LLP

20080051438 - Preventive/therapeutic compositions useful for treating cardiovascular diseases: The present invention provides compositions that exert a superior hypotensive action while inhibiting an increase in heart rate. The present invention provides antihypertensives and preventive/therapeutic compositions useful in the treatment of cardiovascular diseases, which contain cilnidipine and at least one angiotensin II receptor blocker(s). The present invention also provides methods... Agent: Cermak & Kenealy LLP Acs LLC

20080051440 - Compositions for weight management: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows am efficient treatment regime thereof are... Agent: Martin D. Moynihan Prtsi, Inc.

20080051439 - Methods of food intake management: Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The... Agent: Martin D. Moynihan Prtsi, Inc.

20080051442 - Agent for prevention and treatment of cancer comprising oxadiazole urea compound obstructing activity of stat: Disclosed herein is an agent for preventing and treating cancer comprising an oxadiazole urea compound represented by Chemical Formula 1, below, as an effective ingredient. The oxadiazole urea compound effectively inhibits the growth of cancer cell lines and the activity of STAT3, and may be thus useful in the prevention... Agent: Lucas & Mercanti, LLP

20080051441 - Aryl sulphonamide modulators: s

20080051443 - Compounds for the reduction of excessive food intake: The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080051444 - Compounds for the reduction of excessive food intake: The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080051445 - 2-thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-acp reductase of type ii fatty acid synthesis pathway and other cell growth pathways: The current invention presents enoyl-ACP reductase, an enzyme of the type II fatty acid synthesis pathway as a target for treating human malarias and other infectious diseases. We also present in the current invention, 2-thioxothiazolidin-4-ones as antimicrobial and antimalarial agents. We provide 2-thioxothiazolidin-4-ones as antimicrobial and antimalarial agents either alone... Agent: Ladas & Parry

20080051446 - Heterocyclocarboxamide derivatives: The invention relates to a fungicidally active compound of formula (I): where Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, provided that the ring is not 1,2,3-triazole, the ring being substituted by groups R8, R9 and R10;... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080051448 - Stabilized extended release pharmaceutical compositions comprising an amg-coa reductase inhibitor: The present invention is a new stable extended release drug composition particularly suitable for use as an antihypercholesterolaemic or antihyperlipidaemic agent. The present invention is specifically a drug composition comprising a pharmaceutical, a complexing agent and a matrix-forming agent, and a method for manufacturing same. When applied to acid-labile drugs... Agent: Peacock Myers, P.C.

20080051447 - Treatment of hypercholesterolemia, hypertriglyceridemia and cardiovascular-related conditions using phospholipase-a2 inhibitors: The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in... Agent: Ilypsa-mcandrews C/o Mcandrews, Held & Madison Street

20080051449 - Preparation of atorvastatin calcium form vi and compositions thereof: The present invention provides processes to prepare atorvastatin calcium Form VI, pharmaceutical compositions comprising atorvastatin calcium Form VI, and processes to prepare said compositions. An aspect of the invention relates to atorvastatin calcium Form VI compositions having enhanced bioavailability when administered orally to humans.... Agent: Dr. Reddy's Laboratories, Inc.

20080051450 - Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions: This invention describes a process for the production of ANHYDROUS active pharmaceutical ingredients (APIs); a process for the preparation of HYDRATED active pharmaceutical ingredients, a process for the preparation of sterile and stable injectable solutions, and their use, more specifically, APIs which are taxane derivatives, especially (2R,3S) 4-acetoxy-2-α-benzoyloxy-5β-20-epoxy-1,7-β-10-β-tri-hydroxy-9-oxo-tax-11-en-13α-il 3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate (I);... Agent: Birch Stewart Kolasch & Birch

20080051451 - Autoimmune conditions and nadph oxidase defects: The invention relates to methods and materials involved in treating autoimmune conditions. In particular, the invention relates to methods and compounds (and compositions including the compounds) involved in treating, preventing, or delaying the onset of autoimmune conditions. The compounds include one or more isoprenoid units. The compounds can enhance NADPH... Agent: Fish & Richardson PC

20080051453 - Sorbic acid analog co-crystals: The present invention relates to a pharmaceutical co-crystal comprising an active pharmaceutical ingredient and a co-crystal agent having the structure R1—C(═O)XH.... Agent: Amgen Inc.

20080051452 - Hexanoic acid derivatives as dipeptidyl peptidase inhibitors: The present invention is directed to novel hexanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080051454 - Compositions and methods for transient receptor potential vanilloid (trpv) channel mediated treatments: The present inventions relate to therapeutic compositions comprising, and methods utilizing, arachidonic acid derivatives and analogs for treatment of patients demonstrating symptoms of pathological conditions. Specifically, the inventions relate to therapeutic compositions for activating transient receptor potential vanilloid-1 channels (TRPV1). Additionally, therapeutic compositions are provided for increasing TRPV1-type responses. These... Agent: Medlen & Carroll, LLP

20080051455 - Method of treating an animal's exterior for cleaning and/or insect repellency: A method of treating animals to reduce the presence of annoying insects around the animal, help clean the animal's exterior, add luster and sheen to the animal's coat or hide, and provide stain repellency includes the application of a gelled composition to the exterior of an animal. The composition includes... Agent: Clark & Brody

20080051456 - Glycine reuptake inhibitors for treatment of drug dependence: The invention relates to a method of treatment or prevention of drug addiction, in particular alcoholism, in humans, comprising administering to a subject, in need thereof, an effective amount of a Gly-T1 inhibitor, in particular N-methyl-N-[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-phenyl-2-naphthalenyl]methyl glycine or a pharmaceutically acceptable salt thereof.... Agent: Organon Usa, Inc. Patent Department

20080051458 - Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use: Acyloxyalkyl carbamate prodrugs of α-amino acids, pharmaceutical compositions thereof, methods of making acyloxyalkyl carbamate prodrugs of α-amino acids and methods of using acyloxyalkyl carbamate prodrugs of α-amino acids, and pharmaceutical compositions thereof to treat a disease are disclosed. Acyloxyalkyl carbamate prodrugs of α-amino acids suitable for oral administration using sustained... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080051457 - Optically active phthalamide derivative, agricultural or horticultural insecticide, and method of using the same: (wherein each of R1 and R2 represents H, optionally substituted C1-C6 alkyl, or C1-C6 alkoxycarbonyl; R3 represents C1-C6 alkyl; A represents H, C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, optionally substituted phenoxy C1-C6 alkyl, or the like; p represents 0, 1, 2, 3, or 4; q represents 0, 1, or 2;... Agent: Manelli Denison & Selter

20080051459 - Long term 24-hour intestinal administration of levodopa/carbidopa: A method of treating Parkinson's Disease comprising intestinally administering to a patient in need thereof a pharmaceutically effective amount of a composition comprising levodopa and optionally carbidopa continuously over a period of greater than 16 hours.... Agent: Mayer Brown LLP

20080051461 - Peeling process based on surfactants and acids: Process for the treatment of human skin, by applying topically onto the skin a composition containing in a physiologically acceptable medium (i) at least one hydroxy acid selected from the α-hydroxy acids, β-hydroxy acids, α-keto acids, β-keto acids and mixtures thereof, and (ii) at least 5% by weight, relative to... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080051460 - Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease: In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 μg per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring... Agent: Myriad Genetics Inc. Intellecutal Property Department

20080051462 - Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors: The invention relates generally to methods of treating cell proliferative diseases with HSP90 inhibitors and, depending on the specific aspect and embodiment(s) claimed, to the treatment of proliferative diseases that are associated with fusion proteins, e.g., berab1, or mutant proteins or cellular protein isoforms, e.g., mutant forms of p53.... Agent: Biogen Idec / Finnegan Henderson, LLP

20080051463 - Anthracene compounds and their use for treating benign and malignant tumor disorders: The present invention provides novel anthracene compounds according to the formulae (I) and (II) and also selected anthracene compound compounds. The present invention furthermore provides a process for preparing such anthracene compounds. Also provided are pharmaceutical formulations comprising these anthracene compounds. The anthracene compounds provided are particularly suitable for the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080051464 - Protein phosphatase inhibitors: A method of inhibiting protein tyrosine phosphatase in a subject includes administering to the subject a therapeutically effective amount of at least one benzo-1,4-quinone, phenyl isothiazolone, or analog thereof to the subject.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20080051465 - Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, or tetrahydro-isoalpha acids commonly found in hops.... Agent: Mcdermott Will & Emery LLP

20080051466 - Isoalpha acid based protein kinase modulation cancer treatment: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on isoalpha acids, commonly found in hops.... Agent: Mcdermott Will & Emery LLP

20080051467 - Linear and branched alcohol ethoxylates for controlling insects: Compounds for controlling aquatic breeding insects including an ethoxylated alcohol with a carbon chain length of about 10 to about 24 carbon atoms and about 0 to about 16 moles of ethylene oxide per mole of alcohol, where the carbon chain is linear or branched with an alkyl group are... Agent: Cognis Corporation Patent Department

20080051468 - Dual phase cosmetic composition: The present invention relates to a liquid dual phase cosmetic or pharmaceutical composition comprising an oil phase and an aqueous phase, the composition containing as a demixing agent a film forming agent such as polyvinylpyrrolidone and derivatives thereof. The compositions of the invention are particularly useful as makeup removers.... Agent: The Estee Lauder Cos, Inc

20080051469 - Dual phase cosmetic composition: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface... Agent: Foley And Lardner LLP Suite 500

20080051470 - Sensory wax for cosmetic and/or pharmaceutical formulations: A fatty acid ester of pentaerythritol, a pentaerythritol oligomer, or mixtures thereof, where the fatty acid has 6 to 22 carbon atoms, and the ester contains less than 0.3% by weight C17 fatty acid acyl groups and has a melting point of at least 30° C. is provided. A process... Agent: Cognis Corporation Patent Department

  
02/21/2008 > patent applications in patent subcategories. patents and inventions

20080045448 - Reversing autonomic nervous system dysfunction by potentiating methylation: The present invention is a method and composition for reversing dysfunction of the human autonomic nervous system. The invention consists of administering a methylation-promoting composition that promotes uninterrupted recycling of homocysteine to methionine and uninterrupted processing and removal of metabolic products of stress.... Agent: Intellectual Property Strategists, LLC

20080045449 - Novel lipid mixtures for synthetic surfactants: The present invention provides novel lipid mixtures for synthetic surfactants. In particular, the invention provides a specific lipid mixture containing a specific amount of polyunsaturated phospholipids to be used for the preparation of synthetic surfactants. Said surfactants and pharmaceutical compositions thereof are useful for the treatment of surfactant deficiencies like... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080045467 - Composition containing ginsenoside f1 or compound k for skin external application: The present invention relates to an inhibitor for the biosynthesis of gelatinase comprising ginsenoside F1 (20-O-β-D-glucopyranosyl-20(S)-protopanaxatriol) or compound K (20-0-β-D-glucopyranosyl-20(S)-protopanaxadiol), which is a chief metabolite of ginseng saponin, as an active ingredient; and a cosmetic/medical composition for the prevention of skin-aging comprising the same which is superior in inhibiting the... Agent: Sughrue Mion, PLLC

20080045475 - Elemental cellular therapy is a genetic, cellular and disease-modifying therapy which enhances the systemic conduct of genetic and cellular transmethylation activity resulting in enhancement of concerted genetic and cellular metabolic, physiologic and hom: e

20080045477 - Series of new 4,6-diamino-1,2-dihydro-1-aryl-1,3,5-triazines, substituted by an adamantyl moiety in the position 2 of triazine-their corresponding salts, isomers,steroisomers, enantiomers, free bases and the complexes of all the above with natural macromo: A series of new 4,6-diamino-1,2-dihydro-1-aryl-2-(-tricyclo[3.3.1.13,7]decyl]-1,3,5-triazines where the aryl group is a substituted or unsubstituted phenyl, or naphthyl-group, as pharmaceutically accepted salts or as free bases. The phenyl group substituents are halides, alkyls, alkoxyls or nitro group. One or more of the above substituents are found one or more times each... Agent: Watov & Kipnes, P.C.

20080045444 - Compositions and methods for treating cardiovascular disease and myocardial infarction with dipeptidyl peptidase inhibitors or b type natriuretic peptide analogues resistant to prolyl-specific dipeptidyl degradation: The present invention describes compositions and methods for treating cardiovascular disease and myocardial infarction using dipeptidyl peptidase inhibitors. Also provided are methods for increasing natriuretic peptide function by administering one or more analogues of B type natriuretic peptide that provide increased stability in the presence of prolyl-specific dipeptidyl.... Agent: Foley & Lardner LLP

20080045443 - Compositions for inhibiting plexin-a1-dap12 interactions and methods of treating inflammatory, autoimmune or bone resorption diseases using the same: Disclosed are compositions and methods of treating an inflammatory, autoimmune or bone resorption disease by inhibiting plexin-A1-DAP12 interaction, plexin-A1-Trem-2 interaction or DAP12-Trem-2 interaction.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080045445 - Modulating notch1 signaling pathway for treating neuroendocrine tumors: Methods and pharmaceutical compositions for treating or suppressing symptoms of neuroendocrine (NE) tumors comprising increasing the levels or activities of Notch1 protein or other components of the Notch1 signaling pathway of the cancer cells. Also disclosed are pharmaceutical compositions for the methods.... Agent: Baker Donelson Bearman Caldwell & Berkowitz, PC

20080045447 - Fibrilliform-free insulin composition: Compositions and methods are disclosed for treating a patient with insulin, wherein a composition in a form suitable for nasal delivery to a patient comprises a therapeutically effective amount of insulin, a permeation enhancer, a liquid carrier, and an acid present in said composition in an amount sufficient to provide... Agent: Raymond E. Stauffer, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20080045446 - Insulin composition: Pharmaceutical compositions for nasal administration to humans, or to warm-blooded animals, comprise: (A) a therapeutically effective amount of insulin; (B) a permeation enhancer; and (C) a liquid carrier; the compositions being further comprised of, or characterized by, any, or each, of: (D) a combination of non-ionic surfactants; wherein the combination... Agent: Raymond E. Stauffer, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20080045457 - Ancestral hepatitis c virus envelope protein sequence: The present invention provides ancestral sequences for hepatitis C virus (HCV) envelope proteins, as well as uses for such sequences in inducing protective immune responses in subjects infected or at risk of infection with HCV.... Agent: Saint Louis University Office Of Innovation And Intellectual Property

20080045450 - Glp-2 derivatives: Analogs of GLP-2, pharmaceutical compositions comprising GLP-2 analogs, and methods of treating diseases and disorders comprising administering such analogs or compositions are provided.... Agent: Novo Nordisk, Inc. Patent Department

20080045453 - Method of producing biologically active vitamin k dependent proteins by recombinant methods: The invention relates to commercially viable methods for producing biologically active vitamin K dependent proteins, particularly Factor IX. Factor IX is produced at a level of at least about 15 mg/L and is at least 25% biologically active. The method relies upon co-expression of one or more of paired basic... Agent: Knobbe Martens Olson & Bear LLP

20080045451 - Novel thymidylate synthase mutants: Novel thymidylate synthase (TS mutants) are disclosed differing from human wild type thymidylate synthase in single, double, or multiple mutations, which show intact enzyme activity and enhanced resistance to TS-inhibiting drugs like 5-fluorouracil or 5-fluoro-2-deoxyuridinemonophosphate. All these mutants can be used for the protection of normal human cell populations against... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080045458 - Paralytic peptide for use in neuromuscular therapy: The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.... Agent: Synnestvedt & Lechner, LLP

20080045454 - Polynucleotide encoding a trim-cyp polypeptide, compositions thereof, and methods of using same: The invention provides an isolated nucleic acid encoding a TRIM—cyclophilin A fusion sequence encoding a TRIMcyp fusion protein which is active as an anti-viral agent, and in particular an anti-HIV-1 agent. The invention provides for a nucleic acid encoding a polypeptide having both TRIM activity and cyclophilin activity. The invention... Agent: Wilmerhale/columbia University

20080045455 - Rage fusion proteins, formulations, and methods of use thereof: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20080045452 - Regulation of cytokine synthesis and release: Methods of treatment and prevention of diseases associated with release of neutrophil elastase and IL-8 by administration of TFPI and analogs of TFPI are disclosed. Methods of determining efficacy of treatment with TFPI, patient's responsiveness to treatment with TFPI, and the ultimate determination of patient prognosis are also disclosed.... Agent: Novartis Vaccines And Diagnostics Inc.

20080045456 - Treatment of disease: The invention relates to the use of angiogenin, or a fragment or variant thereof, to treat diseases or conditions characterised by neuronal injury or death, or axonal degeneration, especially neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). The invention also describes a plurality of mutations of the human angiogenin gene... Agent: Wolf Greenfield & Sacks, P.C.

20080045459 - Orally administered peptides synergize statin activity: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention... Agent: Beyer Weaver LLP

20080045461 - N-terminally modified glp-1 receptor modulators: The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that may... Agent: Louis J. Wille Bristol-myers Squibb Company

20080045460 - Treatment of prostate cancer by inhibiting lyn-tyrosine kinase: The present invention concerns methods for the treatment of prostate cancer by the inhibition of Lyn-kinase associated signal transduction. Preferred in accordance with the invention are inhibitors which comprise sequences derived from specific regions of the Lyn-kinase.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080045462 - Use of pentagastrin to inhibit gastric acid secretion or as a diuretic: This invention pertains to the discovery that pentagastrin, when administered in conjunction with a proton pump inhibitor (PPI) is synergistic with the PPI and significantly increases the efficacy of the PPI in reducing/mitigating excess gastric acid secretion.... Agent: Beyer Weaver LLP

20080045463 - Methods for lowering hif-1 mediated gene expression: The present invention relates to the elucidation of specific molecular features of endogenous amino acids and their derivatives for inhibiting hypoxia-inducible gene expression by preventing inactivation of hypoxia-inducible factor hydroxylating enzymes. This invention encompasses agents that can be used to reduce tissue vascularization, cancer cell survival, and to treat obesity.... Agent: Morgan Lewis & Bockius LLP

20080045464 - Natural sweetener: The invention relates to extracts, in particular non-nutrient phytochemicals, form sugar cane or sugar beet waste products, such as molasses, sugar mud and bagasse, which have Glycemic Index (GI) lowering properties and their use as sweeteners and in foods containing sugar.... Agent: Ip Group Of Dla Piper US LLP

20080045465 - Phosphole derivatives complexed with metals, and pharmaceutical uses thereof: The invention concerns pharmaceutical compositions comprising as active compound at least one compound of general formula (A), wherein: M represents a metal atom, and their uses in particular for preventing or treating pathologies associated with an excess activity of glutathion reductase and/or thioredoxin reductase.... Agent: Young & Thompson

20080045466 - Progression inhibitor for disease attributed to abnormal accumulation of liver fat: The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for... Agent: Sughrue Mion, PLLC

20080045468 - Antimicrobial 2-deoxystreptamine compounds: The present invention is directed to analogs of paromomycin having a variety of chemical functional groups attached at the 2″-O-position as well as their preparation and use as prophylactic or therapeutics against microbial infection.... Agent: Seed Intellectual Property Law Group PLLC

20080045470 - Ceramides and apoptosis-signaling ligand: The invention provides the compounds of formula ( ): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, A, X, Y, a, b and n are as defined herein. Also disclosed are methods for making the compounds of formula (I) and their use in treating or preventing diseases associated... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080045469 - Compositions and methods for inhibiting angiogenesis: Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is one of the most frequently expressed angiogenic factors in tumors. Development of VEGF antagonists has become an important approach in cancer therapy. Here we describe a novel anti-VEGF strategy by preventing VEGF secretion in tumors cells. We utilize the fact that placenta... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080045473 - Compositions and methods for oligonucleotide formulations: The present invention relates generally to immunostimulatory nucleic acids, compositions thereof and methods of using the immunostimulatory nucleic acids. In particular the invention relates to palindrome-containing immunostimulatory nucleic acids and the use of these nucleic acids in treating disease.... Agent: Wolf Greenfield & Sacks, P.C.

20080045474 - Method for treatment of invasive cells: A method for treating metastatic tumor cells of a subject is disclosed. The method comprises administrating to the subject an antisense molecule comprising a nucleotide sequence which is complementary to an RNA sequence of a protease activated receptor (PAR) protein, or an antibody molecule capable of binding to a PAR... Agent: Oliff & Berridge, PLC

20080045471 - Nucleic acids for apoptosis of cancer cells: The disclosure relates to nucleic acids having Apoptotic Sequence Nos. 5, 8, 9, 11, 14, 60 and 66. It also relates to agents targeting Apoptotic Sequences, said agents having SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 5, SEQ ID NO:6, and SEQ... Agent: Baker Botts L.L.P. Patent Department

20080045472 - Targets for human micro rnas in avian influenza virus (h5n1) genome: The present invention relates to targets for Human microRNAs in Avian Influenza Virus (H5N1) Genome and provides specific miRNA targets against H5N1 virus. Existing therapies for Avian flu are of limited use primarily due to genetic re-assortment of the viral genome, generating novel proteins, and thus escaping immune response. In... Agent: Seed Intellectual Property Law Group PLLC

20080045476 - Methods and compositions using sulodexide for the treatment of diabetic nephropathy: The present invention provides oral formulations of Sulodexide for the treatment of diabetic nephropathy in patients with both insulin dependent and non-insulin dependent diabetes mellitus. Oral formulations containing doses adapted for administration to obtain a reduction in albumin. excretion in patients with both micro and macro albuminuria and to produce... Agent: Jones Day

20080045478 - Flavonoid complexes: The invention relates to complexes of specific flavonoid derivatives, to preparations containing derivatives of this type, to corresponding methods for producing said derivatives or preparations containing the latter and to the use of the latter, in particular for the care, preservation or improvement of the general condition of the skin... Agent: Millen, White, Zelano & Branigan, P.C.

20080045479 - Compositions and methods for regulating mammalian keratinous tissue: Skin care compositions and methods for regulating the condition of mammalian keratinous tissue containing an effective amount of a dipalmitoyl hydroxyproline salt and a second skin care compound selected from hexamidine compounds, sugar amine compounds and their combination.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080045480 - Inhibitors of serine proteases, particularly hcv ns3-ns4a protease: The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising... Agent: Vertex Pharmaceuticals Inc.

20080045481 - Novel co-crystal: The present invention relates to a novel co-crystal of 2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate (AZD1152) which is an aurora kinase inhibitor that is useful in the treatment of hyperproliferative diseases such as cancer.... Agent: Astrazeneca R&d Boston

20080045482 - Compositions and methods for the treatment of viral infections: The present invention provides compositions and methods for inhibiting the replication of influenza virus by administering thiophosphonoformic acid alone or in combination with a neuraminidase inhibitor, for example, oseltamivir.... Agent: Townsend And Townsend And Crew, LLP

20080045483 - Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes: The invention relates to compounds of general formula (1): in which R1, R2, R3, R4, R5, A, B, D and E are as defined in Claim 1, and also to the preparation process therefor and the therapeutic use thereof. These compounds can be used in the treatment of pathologies associated... Agent: Millen, White, Zelano & Branigan, P.C.

20080045484 - Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus: Aromatase inhibitors are administered to a female patient prior to endometrial ablation or resection procedures in order to thin the endometrium to a thickness of less than 6 mm, and preferably less than 4 mm, so as to enhance the treatment outcome. Of course, administration of aromatase inhibitors would be... Agent: Rohm&monsanto PLC

20080045485 - Methods of diagnosing synovial disease in a mammal by detecting bacterial dna in synovial tissues from dogs with inflammatory knee arthritis and degenerative anterior cruciate ligament rupture: Method of diagnosing persistent, chronic synovitis and progressive joint degradation in the joint of a mammal. The method including providing a test sample comprising synovial fluid, cell or tissue from the joint of a mammal; detecting the presence of bacterial DNA, measuring the concentration of one or more biomarkers being... Agent: Quarles & Brady LLP

20080045486 - Ocular administration of testosterone: The present invention provides improving health in a woman or man comprising non-orally administering a testosterone-containing moiety to said woman or man by topically applying a liquid composition including said testosterone-containing moiety to the eye of said woman or man in an amount sufficient to provide a therapeutic effect.... Agent: Allergan, Inc.

20080045487 - Pharmaceutical formula for treating skin disease: The present invention refers to a pharmaceutical formulation characterized in that it includes mainly clobetasolpropionate, minoxidil and 11 alpha hydroxyprogesterone as main active principles, besides other excipients, vitamins and/or minerals, and to its use in the treatment of skin diseases, mainly in the symptomatic treatment of psoriasis.... Agent: Klauber & Jackson

20080045489 - 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands: Disclosed are novel cyclobutenedione Compounds 1 to 18 comprising a cyclobutenedione ring, a substituted phenyl ring, and a —CH(C2H5)-furan moiety. The phenyl ring and the —CH(C2H5)-furan moiety are each bound to the cyclobutenedione ring through a —NH— moiety. Also disclosed are methods of treating chemokine mediated diseases (e.g., cancer, COPD,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080045488 - Prevention of ovarian cancer by administration of products that induce biological effects in the ovarian epithelium: The present invention relates to compositions and methods for preventing the development of epithelial ovarian cancer by administering compounds in an amount capable of regulating TGF-β expression in the ovarian epithelium and/or capable of optimally altering expression of other surrogate biomarkers identified by microarray technology. HRT and OCP regimens comprising... Agent: Jenner & Block, LLP

20080045490 - Pharmaceutical compositions: The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of... Agent: Hollis-eden Pharmaceuticals, Inc.

20080045491 - Surface sanitizer: A non-toxic antimicrobial surface sanitizer composition comprising a water-miscible alcohol, water, a weak acid and a multivalent cation (e.g., metal ion or metal compound). The composition may also include one or more of an emollient, oxidative agent, humectant, lubricant, plant-derived alkene, antimicrobial component or plant-derived essential oil. These compositions can... Agent: Knobbe Martens Olson & Bear LLP

20080045492 - Mitotic kinesin inhibitors: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20080045495 - Treatment of patients with cystic disease by alteration of fibrocystin proteolysis: The present invention includes methods and compositions for reducing cyst formation in a patient with polycystic kidney disease by contacting the kidney of the patient with an effective amount of a fibrocystin cleavage inhibitor sufficient to reduce cyst formation, wherein the fibrocystin cleavage inhibitor comprises at least one of a... Agent: Chalker Flores, LLP

20080045494 - Pyridine analogues vi: e

20080045493 - Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor: Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring,... Agent: Wood, Phillips, Katz, Clark & Mortimer

20080045496 - Pyrrolotriazine kinase inhibitors:

20080045497 - Substituted aniline derivatives: The present invention relates to novel analine derivatives and their use in therapy, in particular their use in the treatment of fungal infections.... Agent: Wilson Sonsini Goodrich & Rosati

20080045498 - Polycyclic viral inhibitors: Disclosed are compounds and compositions of Formula (A) and their uses for treating Flaviviridae family virus infections.... Agent: Foley & Lardner LLP

20080045499 - Preferential inhibition of presenilin-1: The invention provides methods for determining whether an agent preferentially inhibits Presenilin-1-comprised γ-secretase relative to Presenilin-2-comprised γ-secretase. The invention also provides agents that preferentially inhibit Presenilin-1-comprised γ-secretase relative to Presenilin-2-comprised γ-secretase, pharmaceutical compositions comprising such compounds, and methods of treating Alzheimer's disease using such compounds. The invention also discloses that... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080045500 - Nerve regeneration stimulator: A nerve regeneration stimulator comprising a compound having a cholinesterase inhibitory activity, a pharmacologically acceptable salt thereof or a solvate thereof.... Agent: Dickstein Shapiro LLP

20080045501 - Pyridobenzazepine compounds and methods for inhibiting mitotic progression: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.... Agent: Millennium Pharmaceuticals, Inc.

20080045502 - Processes for preparing 3-benzazepines: The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.... Agent: Christine A. Goddard Ph.d Cozen O'connor

20080045503 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1: wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-β-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a... Agent: Foley And Lardner LLP Suite 500

20080045504 - Benzonitrile derivatives to treat musculoskeletal frailty: This invention relates to novel amino substituted benzonitrile derivatives and to pharmaceutical compositions containing the novel amino substituted benzonitrile derivatives. This invention also relates to methods of treatment using amino substituted benzonitrile derivatives to prevent and/or restore age-related decline in muscle mass and strength, treat a wasting disease, treat a... Agent: Pfizer Inc

20080045505 - 1-benzoyl substituted diazepine derivatives as selective histamine h3 receptor agonists: The present invention relates to novel diazepanyl derivatives of formula (I) having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080045508 - Substituted aminomethyl benzamide compounds: Certain substituted aminomethyl benzamide compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20080045507 - Substituted benzamide modulators of the histamine h3 receptor: Certain substituted benzamide compounds are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20080045509 - Substituted benzyl amine compounds: Certain substituted benzyl amine compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20080045506 - Pyrrolidine derivatives as histamine receptors ligands: The present invention relates to pyrrolidine derivatives of formula (I) having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080045511 - Non-nucleoside reverse transcriptase inhibitors: The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein A is A1, A2, A3 or A4 and R1, R2, R3, R4a, R4b, R5, R6, Ar, X1, X2,... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20080045510 - Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof: The present invention relates to succinic acid salt forms of the 5-HT1A binding agent 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline, as well as crystalline forms thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Fish & Richardson P.C.

20080045512 - Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane: Formula I is also known as 4-(5-methyloxazolo[4,5-b]pyridine-2-yl)-1,4-diazabicyclo[3.2.2]nonane. The benzoate salt of the invention is useful in the treatment of schizophrenia and Alzheimer's Disease. It is particularly of use in the treatment of cognitive deficits associated with schizophrenia, cognitive and attention deficit symptoms of Alzheimer's Disease, and neurodegeneration associated with Alzheimer's... Agent: Pfizer Inc Steve T. Zelson

20080045513 - Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent: Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. Esters of alkylcarbamic acids are disclosed that are inhibitors of FAAH activity. Compounds disclosed herein inhibit FAAH activity and further provide an analgesic, anti-inflammatory, or anti-pyretic agent. Described herein is a process for... Agent: Organon Usa, Inc. Patent Department

20080045514 - 3-aryl-6-aryl-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof: wherein Ar1, Q2, R1, R2, dashed line and X are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080045515 - Cyclic sulfonamides for inhibition of gamma-secretase: e

20080045516 - Viral polymerase inhibitors:

20080045517 - 6h-thieno[2,3-b]pyrrole derivatives as antagonists of gonadotropin releasing hormone (gnrh):

20080045518 - Oxazinan-2-one derivatives useful as pr modulators: wherein R1-R6, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas,... Agent: Wyeth Patent Law Group

20080045519 - Method to fight against insects including the use of hydrocarbon compounds: Method of fighting against insects including the use of a hydrocarbon compound mixture chosen among alkanes or alkenes comprising from 20 to 40 carbon atoms. Hydrocarbon compound mixture according to this invention. Insecticide composition including a hydrocarbon compound mixture according to the invention in mixture with one or several insecticide... Agent: William O Gray Iii Ostrolenk Faber Gerb & Soffen

20080045520 - Substituted pyrrolidine derivative: t

20080045521 - Phenylalanine derivatives: The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases... Agent: Astrazeneca R&d Boston

20080045522 - Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells: The process for their preparation and pharmaceutical preparations thereof are also described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbate recruitment of polymorphonuclear leukocytes (leukocytes PMN) and of monocytes at the inflammatory sites. In particular, the invention relates to... Agent: Birch Stewart Kolasch & Birch

20080045523 - Synthesis of polyoxygenated nitrogen systems, comprising reactions between enamines of 1,3-dioxan-5-ones and nitroolefins: The invention relates to the synthesis of polyoxygenated nitrogen systems, comprising reactions between enamines of 1,3-dioxan-5-ones and nitroolefins. More specifically, the invention relates to the reaction between enamines having formula II which are derived from 1,3-dioxan-5-ones I and nitroolefins having formula III. In this way, novel polyoxygenated nitrogen systems are... Agent: Intellectual Property / Technology Law

20080045525 - Piperazinyl-pyridine analogues: wherein variables are as described herein. Such compounds are ligands that may be used to. modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods... Agent: Edwards Angell Palmer & Dodge LLP

20080045524 - Selective npy (y5) antagonists: This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20080045526 - Heteroaryl dihydroindolones as kinase inhibitors: i

20080045527 - Immunomodulating heterocyclic compounds: wherein R1 and R3 independently represent H; F; Cl; Br; —NO2; —CN; C1-C6 alkyl optionally substituted by F or Cl; or C1-C6 alkoxy optionally substituted by F; R4 represents a carboxylic acid group (—COOH) or an ester thereof, or —C(═O)NR6R7, —NR7C(═O)R6, —NR7C(═O)OR6, —NHC(═O)NR7R6 or —NHC(═S)NR7R6 wherein R6 represents H, or... Agent: Banner & Witcoff, Ltd.

20080045528 - 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling: Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or... Agent: Novartis Vaccines And Diagnostics Inc.

20080045529 - Use of thienopyrimidines: The invention relates to compounds of formula (I), wherein R1, R2, R3, R4, X and n have the meanings cited in claim (1). Said compounds are inhibitors of tyrosinkinases, especially TIE-2, and Raf-Kinases and can be used, for example, in the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20080045530 - Organic compounds and their uses: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.... Agent: Novartis Corporate Intellectual Property

20080045531 - Anti-inflammatory medicaments: Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.... Agent: Hovey Williams LLP

20080045532 - Compounds which potentiate ampa receptor and uses thereof in medicine: v

20080045533 - Novel cyclohexyl sulphones:

20080045534 - Derivatives of 1,3-diamino benzene as potassium channel modulators:

20080045536 - Fused heterocyclic compounds useful as kinase modulators:

20080045535 - Prokineticin 2 receptor antagonists:

20080045539 - Fused bicycloheterocycle substituted azabicyclic alkane derivatives: The invention relates to fused bicycloheterocycle substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.... Agent: Robert Deberardine Abbott Laboratories

20080045538 - Nitro and amino substituted topoisomerase agents: wherein R1-R9, W, and X have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for... Agent: Viksnins Harris & Padys Pllp

20080045537 - Chemical compounds: The present invention provides compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 of a target cell.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080045540 - Sulfonyl pyrrolidines, method for producing the same and their use as drugs: e

20080045541 - Dihydropyridinone derivatives: The invention relates to novel dihydropyridinone derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.... Agent: Jeffrey M. Greenman

20080045542 - Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof: The disclosure concerns substituted imidazoles and pyrroles, compositions containing the same, the preparation thereof, and the use thereof as medicaments, particularly as anti-cancer agents.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080045543 - Arylpiperazine derivatives and uses thereof: e

20080045544 - Phenyl, pyridine, quinoline, isoquinoline, naphthyridine and pyrazine derivatives:

20080045545 - Ep2 agonists: The invention provides EP2 agonists, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for lowering intraocular pressure and thereby treating glaucoma.... Agent: Pfizer Inc

20080045546 - Tetradydro-naphthalene and urea derivatives: This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity,... Agent: Jeffrey M. Greenman

20080045547 - Salts and co-crystals of pyrazolopyrimidine compounds, compositions thereof and methods for their production and use: The invention provides pharmaceutically acceptable salts and co-crystals of pyrazolopyrimidine compounds such as zaleplon, indiplon and ocinaplon, processes for their preparation, compositions comprising such salts and co-crystals and methods of using such salts and co-crystals for treating various diseases and conditions.... Agent: Black Lowe & Graham PLLC

20080045548 - Pharmaceutical compositions: The present invention relates to pharmaceutical compositions, and more particularly, to a pharmaceutical composition containing the compound {1S-[1α,2α,3β(1S*,2R*),5β]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.... Agent: Pepper Hamilton LLP

20080045549 - Adenosine a2b receptor antagonists: which are adenosine A2B receptor antagonists and, thus, may be employed for the treatment of conditions and diseases mediated by the adenosine A2B receptor activity. Such conditions include, but are not limited to, chronic and acute inflammatory diseases involving degranulation of mast cells, e.g., asthma, allergic rhinitis and allergic dermatitis;... Agent: King Pharmaceuticals, Inc.

20080045550 - Pyrimidine and quinazoline derivatives: wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080045551 - Pharmaceutical combination comprising an adenosine a1 antagonist and a radiocontrast media: Described herein are pharmaceutical combinations comprising a therapeutically effective amount of a first selective adenosine A1 antagonist and a first radiocontrast media. A kit comprising a therapeutically effective amount of the combination of a first selective adenosine A1 antagonist and a first radiocontrast media is also described herein.... Agent: Mayer Brown LLP

20080045552 - Methods of using selective chemotherapeutic agents for targeting tumor cells: A method for treating cancer tumors, particularly ovarian cancer tumors, is described, where fused cyclic pyrimidine having a cancer treating ability is selectively delivered to an FR expressing cancerous tumor.... Agent: Daniel P. Cillo Eckert Seamans Cherin & Mellott, LLC

20080045554 - Purinone derivatives as hm74a agonists: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.... Agent: Pepper Hamilton LLP

20080045555 - Purinone derivatives as hm74a agonists: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.... Agent: Pepper Hamilton LLP

20080045553 - Transdermal administration of phycotoxins: Pharmaceutical compositions for interfering with neuronal transmission comprising an effective amount of at least one tricyclic 3,4-propinoperhydropurine are disclosed. Preparations for facial rejuvenation are provided that comprise an effective amount of the composition of the invention and a facial cream. Methods of interfering with neuronal transmission comprising topical application of... Agent: Knoble, Yoshida & Dunleavy

20080045556 - Oxazolidone derivatives as pr modulators: wherein R1, R2, R5, R6, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or... Agent: Wyeth Patent Law Group

20080045557 - Compounds and methods to inhibit or augment an inflammatory response: Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.... Agent: Schegman, Lundberg, Woessner & Kluth, P.A.

20080045558 - Preparation and utility of opioid analgesics: The present disclosure is directed to modulators of opiate- and/or NMDA receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the use of such compounds for the treatment and/or management of pain, anxiety, neurodegeneration, drug dependence, coughing, muscular tension, and/or glaucoma and any other condition in... Agent: Wilson Sonsini Goodrich & Rosati

20080045559 - Tocopherol-modified therapeutic drug compounds: Tocopherol-modified therapeutic drug compounds; emulsion, microemulsion, and micelle formulations that include the compounds; methods for making the compounds and formulations; methods for administering the compounds and formulations; and methods for treating conditions using the compounds and formulations.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20080045560 - Pyrrolidine and related derivatives useful as pr modulators: wherein R1-R6, R11, R12, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or... Agent: Wyeth Patent Law Group

20080045561 - Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors: e

20080045562 - Substituted thieno[3,2-c]pyridine-7-carboxylic acid derivatives:

20080045563 - Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation:

20080045564 - Quinine products, method of manufacture, method of use: Disclosed herein is a method of using quinine. The method comprises informing a user that quinine does not induce the activity of a cytochrome p450 isozyme.... Agent: Cantor Colburn, LLP

20080045565 - Combinations comprising antimuscarinic agents and beta-adrenergic agonists: s

20080045566 - 6-substituted isoquinoline derivatives: wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 0 or 1; o is 0 or 1; R1 is H, when Y is NH2; or R1 is H, (C1-4)alkyl or halogen, when Y is OH; R2 and R3 are... Agent: Organon Usa, Inc. Patent Department

20080045567 - Therapeutic agent for hyperlipemia and therapeutic agent for diabetes: e

20080045568 - Novel high affinity quinoline-based kinase ligands: Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080045569 - Cyclic amine compound and pest control agent: i

20080045570 - Thiophene-carboxamides useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20080045571 - Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists: e

20080045572 - Pharmaceutical composition comprising roflumilast or the n-oxide of roflumilast: An aqueous pharmaceutical preparation for administration of a slightly soluble PDE4 inhibitor is described.... Agent: Nath & Associates PLLC

20080045573 - Methods and sustained release nicotinic acid compositions for treating hyperlipidemia: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological... Agent: Robert Deberardine D-377/ap6a-1

20080045574 - Anti-trypanosomiasis agent: (wherein R1 and R2 each independently represents a hydrogen atom, halogen atom, hydroxyl group, oxygen atom, C1-5 alkyl group, C1-5 alkoxy group, C5-8 aryl group, C5-8 aryloxy group, C2-6 alkoxycarbonyl group or C2-6 alkylaminocarbonyl group, and may be bound to each other; R3, R4, and R5 each independently represents a... Agent: Morgan & Finnegan, L.L.P.

20080045575 - Delivery of h2 antagonists: The present invention provides methods for treating or preventing periodontal disease in a mammal subject. The inventive methods comprise topically administering to the subject an effective amount of a H2 antagonist encapsulated in liposomes. Preferably, the H2 antagonist, for example, Cimetidine, is encapsulated into paucilamellar liposomes, such as Novasome® microvesicles.... Agent: Choate, Hall & Stewart LLP

20080045576 - Therapeutic n-aryl or n-heteroaryl pyrazolidine and pyrazolidinone derivatives: e

20080045577 - Imidazolidin-2-one derivatives useful as pr modulators: wherein R1-R6, R10, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent... Agent: Wyeth Patent Law Group

20080045578 - Tricyclic oxazolidone derivatives useful as pr modulators: wherein R1-R6, R16, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent... Agent: Wyeth Patent Law Group

20080045579 - Oxazolidine derivatives as pr modulators: wherein R1-R6, m, V, W, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent... Agent: Wyeth Patent Law Group

20080045580 - Novel isoxazole compounds having ppar agonist activity: The present invention relates to novel isoxazole compounds of formula (I) having (PPAR) agonist activity, pharmaceutical compositions containing such compounds and methods for their use.... Agent: Dr. Reddy's Laboratories, Inc.

20080045581 - Ppar active compounds: Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.... Agent: Foley & Lardner LLP

20080045582 - Ena-78 gene polymorphisms and protein concentrations as diagnostic and prognostic tools: The invention concerns polymorphisms in the CXCL5 gene and the concentration of epithelial neutrophil activating peptide (ENA-78) in patients. The invention also pertains to methods and systems for detecting such polymorphisms. The invention further relates to the use of such methods and systems in the diagnosis, prognosis, and treatment selection... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080045583 - Stable levetiracetam compositions and methods: Stable, liquid compositions of levetiracetam that are substantially or entirely free of preservatives, particularly parabens, and/or sugars, such as natural sugars and sugar alcohols. The liquid compositions preferably include oral solutions or suspensions, and may include pharmaceutically acceptable excipients.... Agent: Winston & Strawn LLP Patent Department

20080045584 - Use of docetaxel for treating hepatocellular carcinoma: The present invention is based on the finding that docetaxel is significantly more active against hepatocellular carcinoma cells than paclitaxel at concentrations of up to 1 μM. It accordingly provides the use of docetaxel, or a hydrate thereof, in the manufacture of a medicament for use in the treatment of... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080045585 - Macrocyclic compounds and methods of making and using the same: The present invention provides macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080045586 - Oxydecahydronaphthalene modulators of hm74: Host cells expressing HM74 were used to obtain oxydecalin-like molecules with agonist activity having the following structure:... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080045587 - Plant protection: The invention relates to methods for protecting plants and/or parts of plants from insects and insect larvae and from microbial attack. Said methods comprise the distribution or application of special insecticides or antimicrobial compositions on or to the surface of the plants and/or plant parts and/or the distribution of the... Agent: Paul And Paul

20080045588 - Preparation and utility of substituted amphetamines: Provided herein are substituted amphetamines, processes of preparation and pharmaceutical compositions thereof. Also provided are methods of their use for the treatment and/or management of trauma associated with a terminal disease, a post-traumatic-stress-disorder, or a psychological disorder.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080045589 - Drug combinations with substituted diaryl ureas for the treatment of cancer: The present invention relates to drug combinations and pharmaceutical compositions for treating cancer such as non-small cell lung carcinoma, said combination comprising (1) at least one substituted-diaryl urea such as BAY 43-9006, (2) at least one taxane such as Paclitaxel (Taxol®), Docetaxel (Taxotere®) and Abraxane™ and (3) at least one... Agent: Millen, White, Zelano & Branigan, P.C.

20080045590 - Use of substituted cyclopropane acid derivatives for producing drugs for use in the treatment of metabolic syndrome: Disclosed is the use of certain substituted cyclopropane acid derivatives of Formula 1 as defined herein and of their physiologically tolerated salts for treating metabolic syndrome and related disorders.... Agent: Irving Newman Sanofi-aventis U.s. LLC

20080045591 - Chemical compounds: with the proviso that, when R1═R2=hydrogen, then any optionally substituted C1-10alkyl or optionally substituted C2-10alkenyl for R3 must have a branch point at one or more of the α and β positions counted from the carbonyl group (or tautomeric form thereof) to which R3 is attached; or a physiologically acceptable... Agent: Marshall, Gerstein & Borun LLP

20080045592 - Method of inhibiting growth and proliferation of listeria monocytogenes using levulinate: Methods, formulations and kits containing levulinate or levulinic acid are disclosed that have potent and unexpected properties to inhibit the growth and/or proliferation of Listeria monocytogenes bacteria in a food sample.... Agent: Utah State University Technology Commercialization Office

20080045593 - One part, solids containing decontamination blend composition: A one part, solids containing decontamination blend composition comprises a solid acetyl donor coated with a compound that protects it from hydrolysis, a peroxygen source, optionally a catalyst, optionally a surfactant, and optionally a buffer. The decontamination blend composition is generally in a dry powder, particle, etc. form or in... Agent: Hudak, Shunk & Farine, Co., L.p.a.

20080045594 - Use of at least one conjugated triene-containing fatty acid for preparing a medicine for treating inflammation: The invention concerns the use of at least one conjugated triene-containing fatty acid for preparing a medicine for treating inflammation selected among the group consisting of alpha-eleostearic acid, catalpic acid, calendic acid, jacaric acid, licanic acid and beta-eleostearic acid for making a medicine for treating inflamatory diseases and/or metabolic disorders... Agent: Foley And Lardner LLP Suite 500

20080045595 - Method of treating cancer: The present invention provides therapeutic compounds and methods for the treatment of refractory and multidrug resistant cancers in patients in need of such treatment.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20080045596 - Ep2 receptor agonists: e

20080045597 - Compositions comprising calcium citrate malate and methods for making the same: Compositions containing calcium citrate malate wherein the calcium citrate malate exhibits one or more of: a pore area of at least about 30 m2/g; a dissolution rate of at least about 95% by weight of the calcium citrate malate in less than about 120 seconds.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080045598 - Novel sulfonanilide analogs as selective aromatase modulators (sams): wherein R1 may be alkyl, cycloalkyl, haloalkyl, aryl, substituted aryl, haloaryl, alkoxy, alkylaryl, and arylalkyl; R2 is H, alkyl, aryl, alkylaryl, arylalkyl, and cycloalkyl; R3, with the base nitrogen, forms an amide or sulfonamide; R4 is selected from nitro, amine, amide, and benzamide; or a pharmaceutically acceptable salts thereof Also... Agent: Calfee Halter & Griswold, LLP

20080045599 - Method for increasing the bioavailability of the active form of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl] amino)phenyl] 2-methylpropanethioate: The invention is directed to a method of increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate by administration of a therapeutically effective amount of the drug with food. The invention also provides a kit comprising a pharmaceutical composition comprising a therapeutically effective amount of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and a pharmaceutically acceptable... Agent: Leydig Voit & Mayer, Ltd

20080045600 - Bicalutamide compositions: Pharmaceutical compositions comprising bicalutamide or its pharmaceutically acceptable salts, solvates, single isomers, enantiomers or mixtures thereof, and a hydrophilic excipient, processes for preparing the compositions and finished dosage forms containing them, and methods of use and treatment.... Agent: Dr. Reddy's Laboratories, Inc.

20080045601 - Organic compounds: R1, R2 and R3, independently of each other, signify hydrogen, halogen, nitro, cyano, C1-C6-alkyl, halogen-C1-C6-alkyl, C1-C6-alkoxy, halogen-C1-C6-alkoxy, C2-C6-alkenyl, halogen-C2-C6-alkenyl, C2-C6-alkinyl, halogen-C2-C6-alkinyl, C2-C6-alkenyloxy, halogen-C2-C6-alkenyloxy, C1-C6-alkylthio, halogen-C1-C6-alkylthio, C1-C6-alkylsulfonyloxy, halogen-C1-C6-alkylsulfonyloxy, C1-C6-alkylsulfinyl, halogen-C1-C6-alkylsulfinyl, C1-C6-alkylsulfonyl, halogen-C1-C6-alkylsulfonyl, C1-C6-alkenylthio, halogen-C1-C6-alkenylthio, C1-C6-alkenylsulfinyl, halogen-C1-C6-alkenylsulfinyl, C1-C6-alkenylsulfonyl, halogen-C1-C6-alkenylsulfonyl, C1-C6-alkylamino, di-(C1-C6-alkyl)amino, C1-C6-alkylaminocarbonyl, di-(C1-C6-alkyl)aminocarbonyl, C1-C6-alkylsulfonylamino, halogen-C1-C6-alkylsulfonylamino, C1-C6-alkylcarbonyl, halogen-C1-C6-alkylcarbonyl, C1-C6-alkoxycarbonyl, unsubstituted or one- to... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080045602 - Process for preparation of 3-(2-hydroxy-5methylphenyl)-n, n-disopropyl-3-phenylpropylamine: A new process for preparation of 3-(2-hydroxy-5-methylphenyl)-N,N-diisopropyl-3-phenylpropylamine from 3,4-dihydro-6-methyl-4-phenyl-2-benzopyran-2-one is characterized by intermediates such as 3-(2-hydroxy-5-methylphenyl)-3-phenylpropanol and its sulphonated derivatives and amination in presence of sodium iodide... Agent: Sandoz Inc

20080045603 - Methods for treating at least one condition having mt1 receptor, 5ht2b receptor, and l-type calcium channel activity: The present invention is directed to methods comprising administering a composition comprising a therapeutically effective amount of (R)-verapamil, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats, prevents and/or manages at least one condition having MT1 receptor, 5-HT2B receptor and L-type calcium channel activity and releases... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080045604 - Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations: The invention is of a composition for treatment of non-healing and slow-healing wounds and ulcerations, and for treating and preventing peripheral neuropathy. The composition is primarily characterized by a combination of nitroglycerin and turmeric. Preferred embodiments comprise emollient cream, mineral oil, and zinc oxide.... Agent: Herbert Joe

20080045605 - Image quality in the eye: Pharmaceutical compositions or dietary supplements are provided containing lutein, zeaxanthin, or mixtures thereof in amounts effective to improve image quality in the human eye. Methods are also provided for reducing higher order wavefront aberrations in the human eye to improve image quality by administering to a person in need of... Agent: Nixon & Vanderhye, PC

20080045606 - Production and use of monoglycerides: A higher-yielding process for the production of monoglycerides in which triglycerides are enzymatically reacted with a catalytic amount of an esterase, preferably lipase, that has been activated by the addition of alkaline salts, in the presence of linear or branched alcohols containing 1 to 8 carbon atoms, then the esterase... Agent: Cognis Corporation Patent Department

20080045611 - Methods for the therapeutic use of a carbonic anhydrase inhibitor for reducing spinal cord edema: This invention relates to methods of treating mammals at risk or affected by spinal cord edema by administering a carbonic anhydrase inhibitor that crosses the blood-spinal cord barrier. Among the conditions treated are, but not limited to, spinal cord injury, spinal cord tumors and vascular malformations, spinal infections, transverse myelitis,... Agent: Milan Radojicic

20080045607 - Compositions and methods for treatment of protein misfolding diseases: Disclosed are methods for identifying compounds that modulate huntingtinmediated impairment of protein degradation pathways. Compounds identified by such screens can be used as candidate drugs for the treatment of prevention of polyglutamine diseases such as Huntington's Disease.... Agent: Fish & Richardson P.C.

20080045608 - Gene encoding a guanine nucleotide exchange factor binding to rhoa: A gene encoding a novel protein that binds to a Rho family protein being one group of small GTP binding proteins and is capable of exhibiting a GEF activity, namely, a polynucleotide shown by the nucleotide sequence set forth in SEQ ID NO: 1, or SEQ ID NO: 3, or... Agent: Kilyk & Bowersox, P.l.l.c.

20080045609 - Methods and therapeutics to facilitate liver repair: The present invention provides compositions, formulations and methods for treating liver diseases related to tissue inflammation and progressive fibrosis, e.g., progressive liver fibrosis following either chronic or acute injury. The compositions of the invention provide the chronic use of therapeutic agents to effect liver repair.... Agent: Dianna L Devore Jiva Biosciences, Inc.

20080045610 - Methods for regulating neurotransmitter systems by inducing counteradaptations: The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

  
02/14/2008 > patent applications in patent subcategories. patents and inventions

20080039362 - Combination drug therapy for reducing scar tissue formation: The present invention describes various devices and methods wherein a cytostatic antiproliferative drug, either alone or in combination with other drugs, is placed between internal body tissues to prevent the formation of scar tissue and/or adhesions during healing of a wound or surgical site. Specific devices to achieve this administration... Agent: Jonathan P. O'brien, Ph.d. Miller, Canfield, Paddock And Stone

20080039365 - Rapid acting and long acting insulin combination formulations: A combined rapid acting-long acting insulin formulation has been developed wherein the pH of the rapid acting insulin is decreased so that the long acting glargine remains soluble when they are mixed together. In the preferred embodiment, this injectable basal bolus insulin is administered before breakfast, provides adequate bolus insulin... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080039366 - Particles for inhalation having sustained release properties: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of... Agent: Elmore Patent Law Group, PC

20080039368 - Rapid acting and long acting insulin combination formulations: A combined rapid acting-long acting insulin formulation has been developed wherein the pH of the rapid acting insulin is adjusted so that the long acting glargine remains soluble when they are mixed together. In the preferred embodiment, this injectable basal bolus insulin is administered before breakfast, provides adequate bolus insulin... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080039375 - Phosphorus-containing hepatitis c serine protease inhibitors: The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of... Agent: Elmore Patent Law Group, PC

20080039376 - Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase u is beneficial, novel anabaenopeptin derivatives and intermediates thereof: The use of a compound of formula (I): in a method of manufacturing a medicament for the treatment or prophylaxis of a condition wherein inhibition of carboxypeptidase U is beneficial; specified compounds of formula (I) and compositions comprising a compound of formula (I) and a pharmaceutically acceptable adjuvant, diluent or... Agent: Morgan Lewis & Bockius LLP

20080039379 - Compositions comprising gastrin compounds and their use in diabetes: The invention relates generally to novel compositions and methods comprising a gastrin compound. The compositions and methods provide beneficial effects, in particular sustained beneficial effects, in the treatment of diabetes.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080039394 - Dendroaspis natriuretic peptide: Disclosed is a method of inhibiting the growth of a cancer cell using Dendroaspis natriuretic peptide (DNP), isolated from the Green Mamba snake venom with similar structure to ANP, with or without four cardiac natriuretic peptides i.e., atrial natriuretic peptide (ANP), vessel dilator, long acting natriuretic peptide (LANP), and kaliuretic... Agent: Smith Hopen, Pa

20080039389 - Dosing regimens for neural stem cell proliferating agents and differentiating agents for the treatment of neurological disorders: Effective dosing regimens for neural stem cell proliferating and differentiating agents, kits comprising effective dosing regimens for neural stem cell proliferating and differentiating agents, and uses thereof are provided herein. Such kits and methods can be utilized acutely or chronically to treat a neurodegenerative disease or condition. Furthermore, the compositions... Agent: Fish & Richardson P.C.

20080039402 - Peptides and peptidomimetics binding to cd23: The present invention describes compounds comprising new and useful peptides and peptidomimetics that can bind to CD23. They are capable of reducing inflammatory responses associated with auto-immune diseases, chronic inflammatory diseases, allergies and other inflammatory conditions such as those mediated by the mammalian immune system. Compounds of the present invention... Agent: Nixon & Vanderhye, PC

20080039410 - Inositol 1,4,5-trisphosphate receptor mutants and uses thereof: Disclosed herein are compositions and methods for treating subjects with conditions related to Inositol 1,4,5-trisphosphate receptor (InsP3R). Described herein are mutants of InsP3R, methods of making mutants, and methods of using InsP3R mutants for the treatment of a disease or condition.... Agent: Needle & Rosenberg, P.C.

20080039409 - Method of suppressing cancer: The present invention provides a method for suppressing cancer comprising activating tumor suppressor gene p53 or protein p53 for localizing the protein to the nuclear, and a pharmaceutical composition comprising a substance that promotes activation of tumor suppressor gene p53 or protein p53.... Agent: Dickstein Shapiro LLP

20080039415 - Retrograde transport of sirna and therapeutic uses to treat neurologic disorders: Methods of treating disorders affecting the central nervous system (CNS) are disclosed. More particularly, methods of treating neurological disorders are disclosed which show therapeutic or prophylactic treatment of a mammalian CNS disorder by effecting local administration of an iRNA agent, followed by retrograde transport of the iRNA agent away from... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080039364 - Modulating serum amyloid a interaction with tanis and agents useful for same: The present invention relates generally to a method of modulating the functional activity of a serum amyloid A or derivative, homologue, analogue, equivalent or mimetic thereof and, more particularly, to a method of modulating the functional activity of a serum amyloid A by modulating intracellular levels of Tanis or derivative,... Agent: Seed Intellectual Property Law Group PLLC

20080039363 - Radation therapy methods: The present invention provides methods and kits for mitigating radiation induced tissue damage, improving the effectiveness of radiation therapy, to support bone marrow transplantation, and promoting megakaryocyte production and mobilization and platelet production, each method comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080039367 - Medicinal composition containing diabeted remedy: e

20080039369 - Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind... Agent: Baxter Healthcare Corporation

20080039370 - Stable oxidation resistant powdered hemoglobin, methods of preparing same, and uses thereof: The present invention provides oxygenated hemoglobins in powdered form and methods of preparing a powdered form of a protein, such as hemoglobin, which comprise (a) mixing a solution of the protein with inulin, and optimally with a reducing sugar such as glucose or tagatose, and (b) drying the mixture. Also... Agent: Amster, Rothstein & Ebenstein LLP

20080039374 - Cross-lined glycopeptide-cephalosporin antibiotics: This invention provides cross-linked glycopeptide—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20080039371 - Erythropoietin liquid formulation: The invention relates to erythropoietin liquid formulations that are stable in storage and to a method for the production thereof. The invention particularly relates to erythropoietin liquid formulations, which contain at least four amino acids selected from the group consisting of leucine, isoleucine, threonine, glutamic acid, aspartic acid and phenylalanine,... Agent: Knobbe Martens Olson & Bear LLP

20080039372 - Human chorionic gonadotropin antagonists and methods to prevent ovarian hyperstimulation: The present invention is directed to a human chorionic gonadotropin (hCG) antagonist comprising deglycosylated hCG. Methods of recombinantly producing the hCG antagonist in a glycosylation-deficient host cell are also provided. Methods of treating hCG related conditions including ovarian hyperstimulation syndrome, gestational trophoblastic disease, and hCG related tumors by administering an... Agent: Wilmerhale/columbia University

20080039373 - Pegylated factor vii glycoforms: The invention concerns a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked and/or serine-linked oligosaccharide chains, and wherein at least one oligosaccharide group is covalently attached to at least one polymeric group.... Agent: Novo Nordisk, Inc. Patent Department

20080039377 - Composition comprising a jnk inhibitor and cyclosporin: The present invention is related to a composition comprising a JNK inhibitor and a cyclosporin, in particular for the treatment of neuronal disorders, autoimmune diseases, cancer and cardiovascular diseases.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080039378 - Cyclosporin compositions: Disclosed herein are therapeutic methods, compositions, and medicaments related to cyclosporine.... Agent: Allergan, Inc.

20080039380 - Agent for prophylactic and/or therapeutic treatment of retinopathy: An agent for prophylactic and/or therapeutic treatment of retinopathy, which comprises a hepatocyte growth factor (HGF) as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080039384 - Antiangiogenic peptides: The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino... Agent: Knobbe Martens Olson & Bear LLP

20080039382 - Compositions related to pleiotrophin methods and uses thereof: The present invention relates to compositions and methods useful for stimulating or increasing angiogenesis and inducing repair in damaged or diseased tissue, in vivo. More particularly, the present invention is directed to compositions comprising pleiotrophin and methods of inducing and stimulating angiogenesis particularly in ischemic tissue and cardiovascular tissue. The... Agent: Pepper Hamilton LLP

20080039392 - Crac channel and modulator screening methods: Recent studies by our group and others demonstrated a required and conserved role of Stim in store-operated Ca2+ (SOC) influx and Ca2+ release-activated Ca2+ (CRAC) channel activity. Using an unbiased genome-wide RNAi screen in Drosophila S2 cells, 75 hits were identified that strongly inhibited Ca2+ influx upon store emptying by... Agent: Quine Intellectual Property Law Group, P.C.

20080039396 - Dried blood factor composition comprising trehalose: A method for preparing a stable dried composition of blood factor product containing a stabilizing amount of trehalose in the absence of a stabilizing amount of albumin is disclosed.... Agent: Morrison & Foerster LLP

20080039398 - Formulations and methods for treating dry eye: The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080039381 - Lactalbumin for inhibiting angiogenesis: The use of a biologically active complex of α-lactalbumin, selected from HAMLET (human α-lactalbumin made lethal to tumour cells) or a biologically active modification thereof, or a biologically active fragment of either of these, in the preparation of a medicament for use in the treatments of proliferative disease and in... Agent: Nixon & Vanderhye, PC

20080039393 - Metal-binding therapeutic peptides: The present invention is related methods of delivering MBD peptide-linked agents into live cells. The methods described herein comprise contacting MBD peptide-linked agents to live cells under a condition of cellular stress. The methods of the invention may be used for therapeutic or diagnostic purposes.... Agent: Morrison & Foerster LLP

20080039386 - Methods and compositions for diagnosing and preventing a group b streptococcal infection: The present invention provides a group B streptococcal (GBS) surface antigen, designated epsilon antigen, that is co-expressed with the delta antigen on a subset of serotype III GBS. Epsilon is expressed on more pathogenic Restriction Digest Pattern (RDP) III-3 GBS, but not on RDP types 1, 2, or 4. Accordingly,... Agent: Licata & Tyrrell P.C.

20080039383 - Methods and compositions for inhibiting er-stress induced cholesterol/triglyceride accumulation: The present invention provides methods for preventing the accumulation of cholesterol/triglycerides within mammalian cells. The present methods are based upon the surprising discovery that ER stress in a cell leads to cholesterol/triglyceride accumulation within the cell, which cholesterol/triglyceride accumulation is often a causative factor in the development of any of... Agent: Merchant & Gould PC

20080039399 - Methods and systems for neural maintenance and regeneration: Methods and systems are described that release one or both of a neurotrophin and an inhibitor of the degradation of the neurotrophin within or in the vicinity of a highly innervated tissue. In some embodiments, the method includes regulating the release of the neurotrophin and the inhibitor of degradation over... Agent: Searete LLC Clarence T. Tegreene

20080039395 - Methods for treating septic shock: Methods for the treatment of septic shock are disclosed herein. The methods include the use of a therapeutically effective amount of inhibitory peptides that inhibit TLR activity. The peptides can be used with other agents for the treatment of septic shock. In one embodiment, a therapeutically effective amount of a... Agent: Klarquist Sparkman, LLP

20080039385 - Neublastin variants: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.... Agent: Fish & Richardson

20080039391 - New indications for direct thrombin inhibitors in the cardiovascular field: The invention relates to new indications for direct thrombin inhibitors such as dabigatran etexilate in the cardiovascular field.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080039387 - Novel peptides for use in the treatment of obesity: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the... Agent: Novo Nordisk, Inc. Patent Department

20080039388 - Peptides and peptide derivatives as well as pharmaceutical compositions containing the same: e

20080039397 - Tropoelastin derivatives: The invention relates to derivatives of tropoelastin and variants of those derivatives. The invention further provides expression products and hybrid molecules of the derivatives and variants of the invention. The invention further provides methods for the production of the derivatives, variants, expression products and hybrid molecules. Further provided are formulations,... Agent: Nikolai & Mersereau, P.A.

20080039390 - Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage: The invention relates to the use of a Mechano Growth Factor (MGF) polypeptide or a polynucleotide encoding an MGF polypeptide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart by preventing or limiting apoptosis in... Agent: Nixon & Vanderhye, PC

20080039401 - Interleukin-9 mutein peptides: A C to T DNA variation at position 3365 in exon 5 of the human Asthma Associated Factor 1 (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon 117 of AAF1. When this substitution occurs in both alleles in one individual, it is associated... Agent: Morgan Lewis & Bockius LLP

20080039400 - Treatment and prevention of inflammatory bowel diseases: The present invention relates to the use of heat shock proteins, or fragments thereof, for the treatment and prevention of Inflammatory Bowel Diseases. Preferably bacterial and/or human heat shock proteins, especially those belonging to the HSP60 family, are used.... Agent: Foley And Lardner LLP Suite 500

20080039403 - Alpha-fetoprotein peptides and uses thereof: The invention relates to compounds that include peptide and peptidomimetics that inhibit estrogen receptor dependent cell proliferation. The compounds of the invention are useful for treating cell proliferative disorders or physiological conditions characterized by undesirable or unwanted estrogen induced cell proliferation, including breast cancer.... Agent: Heslin Rothenberg Farley & Mesiti PC

20080039404 - Bifunctional analgesic compounds for opioid receptor agonists and neurokinin-1 receptor antagonists: The present invention provides a novel chimeric compound comprising an agonist opioid receptor binding moiety at its N-terminus and an antagonist neurokinin-1 (NK1) receptor binding moiety at its C-terminus for producing analgesia, a pharmaceutical composition comprising the chimeric compound, a method of making the compound, and a method of treating... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080039405 - Modification of percutaneous absorption of topically active materials: The present invention relates to methods of influencing the flux or surface retention time of a topically active pharmaceutical ingredient through skin and formulations relating thereto.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080039406 - 3,6-bridged tylosin derivatives: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Elmore Patent Law Group, PC

20080039407 - Antibiotic and method of production thereof: The invention relates to a novel antibiotic from the macrolactin group and a microbial method for production of macrolactins and a novel isolated Bacillus subtilis, of application as the producing strain for the known Macrolactin A and the novel derivative.... Agent: William Collard Collard & Roe, P.C.

20080039408 - Use of oxypurinol as an inhibitor of anti-neoplastic agent-induced cardiotoxicity: The disclosure relates to methods of ameliorating or preventing cardiotoxicity caused by anti-neoplastic agents, such as doxorubicin, by administering to a patient oxypurinol, salt or derivatives thereof, before, during or after administration of the anti-neoplastic agent.... Agent: Kenyon & Kenyon LLP

20080039418 - Compositions and their uses directed to huntingtin: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease... Agent: Knobbe, Martens, Olson & Bear, LLP

20080039419 - Integrin-linked kinase and its uses: ILK genetic sequences and methods of use are provided.... Agent: Bozicevic, Field & Francis LLP

20080039420 - Method for inhibiting nox1 gene expression: The present invention relates to compositions and methods for gene-specific inhibition of gene expression by short interfering ribonucleic acid (siRNA) effector molecules. The compositions and methods are particularly useful in modulating gene expression of the NOX1 gene in colon cancer cells.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080039416 - Methods for treating disease by modulating an osmotic stress pathway: The cellular response to osmotic stress ensures that the concentration of water inside the cell is maintained within a range that is compatible with biologic function. Single cell organisms are particularly dependent on mechanisms that permit adaptation to osmotic stress because each individual cell is directly exposed to the external... Agent: Sonnenschein Nath & Rosenthal LLP

20080039421 - Molecular transporters based on alditol or inositol and processes for the preparation thereof: The inventive molecular transporter compound shows significantly high permeability through a biological membrane such as plasma membrane, nuclear membrane and blood-brain barrier, and accordingly, it can be effectively used in delivering various biologically active molecules, such as doxorubicin and paclitaxel to target cells.... Agent: Sughrue Mion, PLLC

20080039413 - Novel compositions and methods in cancer: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel... Agent: Novartis Vaccines And Diagnostics, Inc. Corporate Intellectual Property-r338

20080039417 - Protein tyrosine phosphate mutations in cancers: Tyrosine phosphorylation, regulated by protein tyrosine phosphatases (PTPs) and kinases (PTKs), is important in signaling pathways underlying tumorigenesis. A mutational analysis of the tyrosine phosphatase gene superfamily in human cancers identified 83 somatic mutations in six PTPs (PTPRF, PTPRG, PTPRT, PTPN3, PTPN13, PTPN14) affecting 26% of colorectal cancers and a... Agent: Banner & Witcoff, Ltd.

20080039414 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA... Agent: Mcdonnell, Boehnen, Hulbert And Berghoff, LLP

20080039412 - Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina): The present invention concerns methods and nucleic acid based reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, veterinary, agricultural, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to multifunctional short interfering nucleic acid (multifunctional siNA) molecules that modulate the expression... Agent: Mcdonnell, Boehnen, Hulbert And Berghoff, LLP

20080039411 - Use of resistin antisense oligonucleotides and/or sirna molecules in the treatment of rheumatoid arthritis: The present invention relates to the use of oligonucleotides antisense to part of the resistin gene and siRNA blocking the action of resistin for the treatment of Rheumatoid Arthritis. The present invention also relates to the determination of the onset of rheumatoid arthritis.... Agent: Fish & Richardson P.C.

20080039422 - Vitamin b12-containing compositions and methods of use: The present invention features compositions that include one or more vitamin B12 compounds and one or more excipients that enhance solubility of the vitamin B12 compounds. In aspects of the invention, the excipients are alcohols, in particular ethanol, propylene glycol, a polyethylene glycol (PEG), glycerol, mannitol, sorbitol, Tween 20, or... Agent: Fish & Richardson P.C.

20080039424 - Cosmetic composition comprising at least one polysaccharide chosen from lambda-carrageenans in combination with at least one non-ionic surface-active agent chosen from alkylpolyglucosides, and a method for the cosmetic treatment of keratinous fibers there: The present disclosure relates to a cosmetic composition for the treatment of keratinous fibers, such as the hair, comprising at least one polysaccharide chosen from lambda-carrageenans and at least one non-ionic surface-active agent chosen from alkylpolyglucosides, wherein the at least one polysaccharide is present in an amount ranging from 0.1... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080039423 - Ophthalmic composition containing xanthan gum and amino acid: The present invention provides an ophthalmic composition containing xanthan gum, or xanthan gum and an amino acid, which has a superior corneal epithelial disorder-treating effect and a superior corneal epithelial cell-protecting effect.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080039425 - Methods and compositions to reduce tissue irritation in parenteral formulations: Compositions comprising a therapeutic compound and a dextin are disclosed, as well as processes for the preparation of the compositions. Also disclosed are methods using the compositions, including a method for reducing local irritation and resulting pain from an injection of a therapeutic compound by administering the composition.... Agent: Swanson & Bratschun, L.L.C.

20080039426 - Inhibitors of tyrosine kinases and uses thereof: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated... Agent: Wilson Sonsini Goodrich & Rosati

20080039427 - Method and compositions for treating hematological malignancies: s

20080039428 - Antiretroviral combination therapy: The present invention provides combinations comprising a viral maturation inhibitor and another therapeutically effective pharmaceutical agent. The invention is also directed to methods of treating a viral infection by administering such combinations.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080039429 - Sulfonylethyl phosphorodiamidates: Sulfonylethyl and thioethyl phosphorodiamidates, their preparation and intermediates in their preparation, formulations containing them, and their pharmaceutical use. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.... Agent: Foley & Lardner LLP

20080039430 - Pharmaceutical compositions for the treatment of leishmaniasis: The present invention relates to the use of at least one compound of the following general formula (I): wherein R represents OH or NH2, or of precursors or derivatives thereof, or of the pharmaceutically acceptable salts of the compound or of its precursors or derivatives, for the manufacture of a... Agent: Young & Thompson

20080039431 - Method of improving plant growth by reducing viral infections: A method of improving the growth of a plant is provided by reducing the incidence of one or more insect-vectored viral infections. The method comprises the step of applying a primary treatment composition in-furrow during planting of a seed or seedling or during transplanting of the plant, wherein the primary... Agent: Bayer Cropscience Lp

20080039432 - Active compound combinations having insecticidal properties: This invention relates to active compound combinations containing firstly at least one neonicotinoid selected from the group consisting of clothianidin and imidacloprid and secondly at least one cholinesterase inhibitor selected from the group consisting of ethoprophos and aldicarb that are highly suitable for controlling pests, in particular insects and nematodes.... Agent: Bayer Cropscience Lp

20080039433 - Stabilized tetracycline compositions: The invention provides a package that comprises a first rapidly disintegrating dosage form comprising tetracycline, and a second rapidly disintegrating dosage form that comprises a buffer. The invention also provides methods for treating or preventing mucositis, comprising mixing the dosage forms of the package in an aqueous medium to form... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080039434 - Treatment of interstitial cystitis with vitamin d compounds: There is provided according to the invention a vitamin D compound for use in the prevention and/or treatment of interstitial cystitis. Also provided is a method for preventing and/or treating interstitial cystitis by administering an effective amount of a vitamin D compound.... Agent: Edwards Angell Palmer & Dodge LLP

20080039435 - Novel steroid agonist for fxr: The invention relates to a FXR agonist of formula (I) and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.... Agent: Wilmerhale/dc

20080039436 - Porphyrin derivatives and their use in photon activation therapy: The present invention relates to the use of a compound of formula (I) in the manufacture of a pharmaceuticals composition for cell death by photo activation therapy and the use of the compounds in the prevention and/or treatment of cancer.... Agent: Choate, Hall & Stewart LLP

20080039438 - 1b-methylcarbapenem derivative and process for the preparation thereof: The present invention relates to a novel 1β-methylcarbapenem derivative, a process for the preparation thereof and a pharmaceutical composition comprising the 1β-methylcarbapenem derivative or a pharmaceutically acceptable salt thereof as an active antibacterial ingredient.... Agent: Sughrue Mion, PLLC

20080039437 - New pyridine analogues iii: e

20080039439 - Alpha2c adrenoreceptor agonists: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080039440 - Cyclic diaryl ureas suitable as tyrosine kinase inhibitors: and wherein the radicals have R1, R2, R3 and R4 have the meanings as defined herein, to salts, esters, N-oxides or prodrugs thereof; and their use in the treatment of protein kinase dependent diseases, their use in the manufacture of pharmaceutical compositions for use in the treatment of said diseases,... Agent: Novartis Corporate Intellectual Property

20080039441 - Modified release formulations of a bupropion salt: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080039443 - Manipulation of brain cdp-diacylglycerol and uses thereof: Provided herein methods of screening for potential antidepressant compounds effective to increase production of cellular CDP-diacylglycerol and synthesis of inositol phospholipid in depression-related areas of the brain. Also, provided are methods of diagnosing and treating depressive or mood disorders in a subject by administering these screened antidepressant compounds. Further provided... Agent: Benjamin Aaron Adler Adler & Associates

20080039442 - Compounds with kv4 ion channel activity: The present invention relates to compounds that interact with ion channels. In particular, the invention relates to compounds having the structural Formula (I), (II), (III) or (IV), stereoisomers, tautomers, racemics, prodrugs, metabolites thereof, or a pharmaceutically acceptable salt and/or solvate thereof, Formula (I), (II), (III), (IV), wherein X1, X2, Y,... Agent: Wolf Greenfield & Sacks, P.C.

20080039444 - Compounds: e

20080039445 - Production method of pyrimidine compounds:

20080039447 - Cdk-inhibitory pyrimidines, their production and use as pharmaceutical agents:

20080039446 - Substituted isoindoles and their use:

20080039448 - Pyrrolobenzodiazepines:

20080039449 - Inhibitors of interleukin-1beta converting enzyme: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly... Agent: Ropes & Gray LLP Patent Docketing 39/361

20080039450 - Compounds: wherein X, Y, Z, A, Ar, R1, R2, R3, and R4 are as defined herein, which compounds are inhibitors of MNK2 and MNK1. The invention also relates to the use of the compounds in therapy, pharmaceutical compositions comprising the compounds, and the use of the compounds for the preparation of... Agent: Fish & Richardson PC

20080039451 - Use of thiazole derivatives for preparing a medicament intended to protect the mitochondria: e

20080039452 - Fused quinoline derivative and use thereof:

20080039453 - Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use: Enantiomerically pure R-etifoxine and pharmaceutically acceptable salts, solvates, hydrates or prodrugs thereof are provided. Also provided are pharmaceutical compositions comprising the compounds and methods of treating disorders associated with central nervous system using the compounds and pharmaceutical compositions.... Agent: Jones Day

20080039454 - Urotensin ii receptor antagonists: The invention is directed to Urotensin II receptor antagonists. More specifically, the present invention relates to certain novel compounds and methods for preparing compounds, compositions, intermediates and derivatives thereof. Pharmaceutical compositions and methods for treating or ameliorating a Urotensin-II mediated disorder using compounds of the invention are also described.... Agent: Philip S. Johnson Johnson & Johnson

20080039455 - Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same: e

20080039456 - Rigidified compounds for modulating heparanase activity: Disclosed are novel rigidified compounds having a rhodanine-like residue and at least one aryl or heteroaryl residue linked to the rhodanine-like residue, whereby a core structure of these compounds, as defined in the specification, is characterized as having one or zero free-to-rotate bonds. Also disclosed are pharmaceutical compositions containing these... Agent: Martin D Moynihan Prtsi, Inc.

20080039458 - Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine: s

20080039457 - Triazolotriazines as kinase inhibitors: The present invention is directed to [1,2,4]triazolo[4,3-b][1,2,4]triazines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.... Agent: Fish & Richardson PC

20080039460 - Benzamide derivatives, their manufacture and use as pharmaceutical agents: e

20080039459 - Phosphoinositide 3-kinase inhibitor compounds and methods of use: Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro,... Agent: Viksnins Harris & Padys Pllp

20080039462 - Compounds having 5-ht6 receptor affinity: m

20080039461 - Treatment of pain by inhibition of p38 map kinase: The present invention relates to methods for the prevention or treatment of pain by the inhibition of p38 MAP kinase.... Agent: Morrison & Foerster LLP

20080039463 - Methods and compositions: Compositions of flupirtine for management of neuropathic or inflammatory pain optionally including one or more other analgesics including opiates, NSAIDS and other active agents in immediate and controlled release forms. Methods and systems for administration of these compositions.... Agent: Seed Intellectual Property Law Group PLLC

20080039464 - Compounds which modulate the cb2 receptor: m

20080039465 - Triazolyl phenyl benzenesulfonamides: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of... Agent: Brinks Hofer Gilson & Lione

20080039466 - 2-(3-substituted-aryl) amino-4-aryl-thiazoles as tyrosine kinase inhibitors: The present invention relates to novel compounds selected from 2-(3substitutedaryl)amino-4-aryl-thiazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent... Agent: Foley And Lardner LLP Suite 500

20080039467 - Method for the prevention of thromboembolic disorders: A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders, such as cerebral infarction (stroke) or myocardial infarction, by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need of such prevention.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080039468 - Novel 3-phenyltetrahydrocinnolin-5-ol derivative and medicinal use thereof: A 3-phenyltetrahydrocinnolin-5-ol derivative represented by the following general formula (1) (wherein Z represents 2-carboxyethyl, 3-dimethylaminopropyl etc.; X represents trifluoromethyl etc.; X′ represents hydrogen, etc.; and Y anti Y′ each represents methyl, hydrogen, etc.), a physiologically acceptable salt thereof, or a prodrug of either. They have cytostatic activity against tumor cells... Agent: Nields & Lemack

20080039470 - Acylaminoheteroaryl hepatitis c virus protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20080039469 - Muscarinic agents as therapeutic compounds: Muscarinic agonists of the formula (I) with M1 selectivity which are useful as agents for stimulating the cognitive functions of the brain.... Agent: Welsh & Katz, Ltd

20080039472 - Inhibitors of the interaction between mdm2 and p53: s

20080039471 - Composition and method to inhibit tissue plasminogen activator (tpa) - potentiated neurotoxicity: The present invention relates to methods of treating, preventing or ameliorating ischemia-related, neural cell degeneration in a subject being treated with a thrombolytic agent, by administering to the subject one or more neuroprotective thiosemicarbazone compounds. More particularly, the present invention relates to methods of preventing, treating or ameliorating the adverse... Agent: Panacea Pharmaceuticals, Inc.

20080039473 - Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects: The present disclosure is directed to modulators of alpha-adrenergic receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the use of such compounds for the treatment and/or management of hypertension, cardiac failure, prostatitis, and benign prostatic hyperplasia, and any other condition in which it is beneficial... Agent: Wilson Sonsini Goodrich & Rosati

20080039474 - Novel heterocyclic substituted pyridine compounds with cxcr3 antagonist activity: or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080039475 - Compositions and methods for increasing blood platelet levels in humans: Disclosed in certain embodiments is an oral pharmaceutical dosage form comprising a pharmaceutically acceptable excipient and an effective amount of 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl)piperadine-4-carboxylic acid (Formula I) or a pharmaceutically acceptable salt thereof, to increase platelet levels in humans.... Agent: Davidson, Davidson & Kappel, LLC

20080039476 - Pyrazolopyrimidines, a process for their preparation and their use as medicine: s

20080039477 - Pyrazolopyrimidines as cell cycle kinase inhibitors:

20080039478 - Bicycloheteroaryl compounds as p2x7 modulators and uses thereof:

20080039479 - Compounds and therapeutical use thereof: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20080039480 - Quinazolinedione derivatives as parp inhibitors: s

20080039481 - Seed dressing for soya bean: The use of one or more DMI fungicides from the group consisting of: a) triazoles: a.1. azaconazole, a.2. bitertanol, a.3. bromuconazole, a.4. cyproconazole, a.5. difenoconazole, a.6. diniconazole, a.7. epoxiconazole, a.8. fenbuconazole, a.9. fluquinconazole, a.10. flusilazole, a.11. flutriafol, a.12. hexaconazole, a.13. imibenconazole, a.14. ipconazole, a.15. metconazole, a.16. myclobutanil, a.17. paclobutrazol, a.18.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080039482 - Sulfonamido-macrocycles as tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same: in which R1, R2, R4, R5, R6, A, B, C, L, X, Y, Z, n, and m are as defined in the claims, and salts, N-oxides, or solvates thereof, to pharmaceutical compositions comprising said sulfonamido-macrocycles, to methods of preparing said sulfonamido-macrocycles as well as the use thereof for manufacturing a... Agent: Millen, White, Zelano & Branigan, P.C.

20080039483 - Novel chelidonine derivatives, methods for the production thereof, and use thereof for producing pharmaceutical agents: The invention relates to novel chelidonine derivatives, methods for the production thereof, the use of said compounds for the prevention, treatment, monitoring of the progress, and aftertreatment of diseases related to cell growth, cell differentiation, and/or cell division, especially tumors, and a kit comprising the inventive chelidonine derivatives.... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20080039484 - Methods and compositions for preventing or treating cardiovascular disease: The present invention relates to a method for preventing or treating a cardiovascular disease.... Agent: Wpat, PC Intellectual Property Attorneys

20080039485 - Low-dose-long-term pharmaceutical composition comprising camptothecin derivatives for the treatment of cancers: An oral pharmaceutical composition for the treatment of digestive tract cancers contains an effective amount of a camptothecin derivative dissolved in a non-aqueous solvent. The camptothecin derivative is administered at a dose of about 0.05 to about 1 mg/kg body weight/day. The pharmaceutical composition is particularly suitable for use in... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20080039486 - Production of polyketides and other natural products: The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogues and host cells that produce these compounds. The invention is particularly concerned with methods for the... Agent: Dann, Dorfman, Herrell & Skillman

20080039487 - Processes and intermediates useful for preparing integrase inhibitor compounds: The invention provides processes and intermediates useful for preparing integrase inhibiting compounds.... Agent: Gilead Sciences Inc

20080039488 - Salt of naphthyridine carboxylic acid derivative: 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080039489 - Tetrahydrofuran derivatives for use as inhibitors of matrix metalloproteinases: (

20080039490 - Pyridines for treating injured mammalian nerve tissue: The invention provides novel pyridines, pharmaceutical compositions comprising such pyridines, and the use of such compositions in treating injured mammalian nerve tissue, including but not limited to an injured spinal cord, in one embodiment, the compounds, compositions, and methods of the instant invention treat a mammalian nerve tissue injury by... Agent: Ice Miller

20080039491 - Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use: The disclosure relates to substituted pyrazolo-pyridines, compositions containing them, methods for the production thereof, and to their use as medicaments, in particular, as anticancer agents.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080039492 - Quinine products, method of manufacture, and method of use: Disclosed herein is a method of using quinine. In one embodiment, the method comprises obtaining quinine from a container associated with published material providing information that quinine affects the activity of a cytochrome p450 isozyme. In another embodiment, the method comprises informing a user that quinine affects the activity of... Agent: Cantor Colburn, LLP

20080039493 - Quinuclidine derivatives as m3 antagonists: s

20080039494 - 8-phenyl-5,6,7,8-hydroquinoline tachykinin receptor antagonists: The present invention is directed to certain 8-phenyl-5,6,7,8-hydroquinolinecompounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the... Agent: Merck And Co., Inc

20080039495 - Diamine beta2 adrenergic receptor agonists: The invention provides novel β2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20080039496 - Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist: The present invention provides methods of modulating neurite outgrowth in an animal. The methods comprise a general administration of galanin-3 receptor antagonists under conditions sufficient to produce neurite outgrowth.... Agent: Heller Ehrman LLP

20080039497 - Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases: The invention relates to the use of a chemical substance selected from the group consisting of N-′2-hydroxy-3-(1-piperidinyl)-propoxyl !-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixtures of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compounds in the preparation of a pharmaceutical composition for the treatment... Agent: Ropes & Gray LLP Patent Docketing 39/361

20080039498 - Non-competitive nmda receptor antagonists: Disclosed herein are non-competitive NMDA receptor antagonists having chemical structures similar to that of phencyclidine (PCP). These antagonists contain a polycyclic ring structure in place of the cycloalkyl ring of PCP. The antagonists also differ from PCP in that they include an electron withdrawing group, a hydroxyl group, or an... Agent: Duane Morris, LLPIPDepartment

20080039499 - Chemical compounds: The use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, Ra, R8, R2, R3 and R4 are as defined in the specification, in the preparation of a medicament for the treatment of C—C chemokine mediated conditions. Novel compounds of formula (I) and... Agent: Morgan Lewis & Bockius LLP

20080039500 - Cerebral infarction suppressant: An object of the present invention is to provide a cerebral infarction suppressant which is effective for brain tissue necrosis attributed to long-time ischemia as in actual cerebral infarction and has fewer side effects. The suppressant for cerebral infarction attributed to long-time ischemia according to the present invention is characterized... Agent: Fitch, Even, Tabin & Flannery

20080039501 - Hydrate forms of amg706: The anti-angiogenic drug AMG 706 is provided in the mono-phosphate hydrate form. Also provided is AMG 706 drug substance wherein the AMG 706 is present, in at least a detectable amount, as AMG 706 phosphate dihydrate. Also provided are processes for preparing AMG 706 phosphate dehydrate, AMG 706 drug substance... Agent: Amgen Inc.

20080039502 - Ep4 receptor antagonists: e

20080039503 - Process for the preparation of crystalline modifications for use in the preparation of esomeperazole sodium salt: The present invention relates to a new process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt. Further, the present invention also relates to the use of the new crystal modifications for the treatment of gastrointestinal disorders, pharmaceutical compositions containing them as well as... Agent: White & Case LLP Patent Department

20080039504 - Triazolyl pyridyl benzenesulfonamides: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of... Agent: Brinks Hofer Gilson & Lione

20080039505 - Therapeutic lactams: m

20080039506 - Aminoalcohol derivatives: The present invention relates to a compound of the formula [I]: wherein (a), in which —Y—, R4, R5 and R6 are4 R5 each as defined in the description, etc., R1 is hydrogen, halogen, lower alkyl, hydroxy, etc., R2 is hydrogen, lower alkyl or hydroxy(lower)alkyl, R3 is hydrogen or an amino... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080039509 - Histone deacetylase inhibitors or novel benzamine derivatives with potent differentiation and anti-proliferation activity: The present invention is related to the preparation and pharmaceutical use of novel benzamide derivatives as defined in the specification of formula (I) as histone deacetylase inhibitors (HDACI), their preparations and the methods of using these compounds or their pharmaceutically acceptable salt in the treatment of cell proliferative diseases, e.g.... Agent: Foley & Lardner LLP

20080039507 - Novel prostamides for the treatment of glaucoma and related diseases: Disclosed herein are compositions comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma.... Agent: Allergan, Inc.

20080039508 - Treatment of tumours: The present invention provides the use of a metal ion chelating agent for the manufacture of a medicament for the treatment or prophylaxis of a bacteria-mediated cancerous tumour. The metal ion chelating agent provides a metal ion chelating capacity for at least one metal ion on which the tumorigenic bacteria... Agent: Myers Bigel Sibley & Sajovec

20080039510 - (1,5-diphenyl-1h-pyrazol-3-yl)oxadiazole derivatives, preparation method thereof and use of same in therapeutics: e

20080039511 - Thiazole compound and use thereof: wherein R1 is a di-C1-6 alkoxyphenyl group; R2 is any one of the following groups (a) to (t): (a) a phenyl group; (b) a naphthyl group; (c) a pyridyl group; (d) a furyl group; (e) a thienyl group; (f) an isoxazolyl group; (g) a thiazolyl group; (h) a pyrrolyl group;... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080039512 - Use of ppar agonists for the treatment of congestive heart failure: e

20080039513 - Marine compounds with calcium channel blocking properties for the treatment of cognitive or neurodegenerative diseases: The invention provides compounds having a spiro heterocyclic unit connected through a linker of a certain length to another spiro cycle, an imidazole ring or an amide group. Some of these compounds have been obtained from Aplysinia cavernicola and a mixture of Aplysina fulva and Oceanapia. The compounds exhibit VDCC... Agent: Intellectual Property / Technology Law

20080039514 - Compounds for the treatment of dyslipidemia and other lipid disorders: A class of compounds having Formula I and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of developing conditions and sequelae that are associated with these diseases,... Agent: Merck And Co., Inc

20080039515 - Arylpyrazoles and methods of using same for control of insect pests that bore into trees: Insecticidally effective agents are provided which reduce the damage caused to trees by a variety of insect pests which bore into trees. In particular, arylpyrazoles may be used to reduce the damage caused to trees by insect pests or to control insect pests, such as the southern pine beetle, by... Agent: Hutchison Law Group PLLC

20080039516 - Composition of solifenacin or salt thereof for use in solid formulation: A solid pharmaceutical preparation of solifenacin or a salt thereof, the preparation being stable and inhibited from decomposing with time when supplied to clinical fields. In a pharmaceutical preparation containing solifenacin or a salt thereof, the compound in an amorphous form was revealed to be causative of cardinal-drug decomposition with... Agent: Sughrue-265550

20080039517 - Pyrrolidinone anilines as progesterone receptor modulators: s

20080039518 - Maleiimide anti-tumor phosphatase inhibitors: The present invention features maleiimide compounds, pharmaceutical compositions of maleiimide compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more maleiimide compounds of the invention.... Agent: Edwards Angell Palmer & Dodge LLP (client Reference No. 47992)

20080039519 - Anti-demodicosis agent: The present invention relates to the use of macrocyclic lactones for treating demodicosis, particularly in dogs.... Agent: Shook, Hardy & Bacon LLP Intellectual Property Department

20080039520 - Anti-first-pass effect compounds: Safe, effective first-pass inhibiting compounds and citrus-derived substances are provided. Formulations containing the compounds are also provided as are methods for their preparation and for inhibiting the first pass effect.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080039521 - Anticancer effect enhancer: An object of the present invention is to provide an enhancing agent for effect of anticancer agent for achieving an excellent therapeutic effect on cancer. The enhancing agent for effect of anticancer agent according to the present invention which is a solving means therefor is characterized in that a nitric... Agent: Kratz, Quintos & Hanson, LLP

20080039522 - Composition containing a complex comprising a metal ion and a carboxylate ligand having anti-inflammatory activity: A pharmaceutical composition comprising a metal complex of a carboxylate having anti-inflammatory activity in a pharmaceutically acceptable carrier, wherein: (1) the composition has a colloidal structure, or forms a colloidal structure when administered to a human or animal, or is immiscible with water; (2) more than 80% of the total... Agent: Edwards Angell Palmer & Dodge LLP

20080039523 - High volume and alternative methods of delivering homeopathic remedies: An alternative method of delivery of homeopathic medicines by targeting delivery to the MALT's, especially of the intestinal tract and in high volumes.... Agent: Bryan Cave LLP

20080039524 - Methoxypolyethylene glycol thioester chelate and uses thereof: The present invention is directed generally to protecting cells, tissues and organs against the damaging effects of ionizing or other damaging agents associated with radiation or chemotherapy, or degenerative diseases or processes of various organs that elicit the production of free radicals or oxidants such as peroxides, superoxide anions, hydroxyl... Agent: Wilmerhale/dc

20080039525 - Lipid system and methods of use: The present invention relates to a lipid system, and methods for using such a lipid system, containing specific relative ratios of omega-3, omega-6, and omega-9 fatty acids. The lipid system may be used independently or as a component of a nutritional product. A lipid system according to the present invention... Agent: Nickki L. Parlet Ross Products Division Of Abbott Laboratories

20080039526 - Compositions for promoting sleep: An object of the present invention is to provide a composition for promoting sleep, which any one can safely take on a daily basis without any risks of adverse action. In addition, an object of the present invention is to provide food and a medicament, comprising the above-mentioned composition, having... Agent: Birch Stewart Kolasch & Birch

20080039527 - Calixarenes as inhibitors of protein kinase b: The present invention provides compounds useful in inhibiting protein kinase B (PKB/Akt). Compositions comprising such compounds and their use are also provided.... Agent: Elmore Patent Law Group, PC

20080039528 - Zinc finger ejectors and methods of use thereof: Techniques for the chelation or ejection of Zn2+ from zinc finger peptides are disclosed, which can be useful in the treatment or control of viruses and viral diseases and malaria. The invention comprises contacting a zinc finger peptide with an effective amount of a bishydroxamic acid or salt thereof, either... Agent: Hovey Williams LLP

20080039529 - Adjunctive therapy for depression: This invention is directed to a method of treating depression in a subject, comprising the step of administering a therapeutically effective amount of a conventional antidepressant and, in addition, administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or ester... Agent: Gibbons P.C.

20080039530 - Methods of inhibiting vascular permeability and apoptosis: Agonist of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated froms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial... Agent: Cantor Colburn, LLP

20080039531 - Compositions, and kits comprising targeted aldehyde or acetal protease inhibitor compounds for treating muscle disorders: Described herein are compounds that comprise a carrier residue that is or is an analog of carnitine, an optional linker group, and a residue of a protease inhibitor comprising an aldehyde group or acetal derivatives of the aldehyde group, and pharmaceutical compositions and kits thereof. The compounds, compositions, and kits... Agent: Needle & Rosenberg, P.C.

20080039532 - Compounds for specific viral target: The present application relates to a compound having a formula 1: B—R1-R2-M wherein B is a binding element for recognizing and binding a target; R1 is a first group of atoms for reacting with a functionality of the target so as to form a covalent bond with the target; R2... Agent: Fish & Richardson PC

20080039533 - Bioactive compositions comprising triazines: Compositions and methods including a bioactive compound and a triazine compound comprising: formula (I) or formula (II) and proton tautomers and salts thereof . Each R2 is independently selected from any electron donating group, electron withdrawing group and electron neutral group. R3 is selected from the group consisting of substituted... Agent: 3m Innovative Properties Company

20080039534 - Methods for identifying modulators of rgs21 activity, compositions comprising an rgs21 modulator, and methods of use thereof to modulate taste sensation: The present invention provides methods for identifying compounds that selectively and specifically modulate RGS21 gene expression, RGS21 protein expression, and/or the interaction of RGS21 with G proteins in taste signal transduction. In particular, the present invention provides methods for identifying modulators of RGS21 activity for enhancing sweet taste, or other... Agent: Sutherland Asbill & Brennan LLP

20080039535 - Methods of identifying agents for treating neurological disorders: Methods of identifying agents for treatment of schizophrenia and related disorders.... Agent: Pillsbury Winthrop Shaw Pittman, LLP

  
02/07/2008 > patent applications in patent subcategories. patents and inventions

20080032915 - Cysteine rich peptides for improving thiol homeostasis: Described is the use of a mixture of peptides, the peptides comprising at least 6.5% wt cysteine, for the manufacture of a medicament, supplement, beverage or food product for restoring thiol homeostasis. Furthermore, a method is described for restoring thiol homeostasis in a subject in need thereof, said method comprising... Agent: The Webb Law Firm, P.C.

20080032924 - Antifungal peptides: The present invention provides antifungal and antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes such as; protecting plants from fungal infections, treating fungal infections of... Agent: Cooper & Dunham, LLP

20080032936 - Quinoxalinyl tripeptide hepatitis c virus inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Edwards Angell Palmer & Dodge LLP

20080032938 - Compositions containing chalcones and use thereof: The present invention features composition comprising a chalcone and the use thereof for treating acne and reducing the appearance of oil or pores on the skin, hair and scalp.... Agent: Philip S. Johnson Johnson & Johnson

20080032946 - Method for producing a composite made of oligonucleotides or polynucleotides and hydrophobic biodegradable polymers as well as composite obtained according to the method: A method for producing a composite made of oligonucleotides or polynucleotides and hydrophobic biodegradable polymers. The method comprises the following steps: (i) producing an aqueous solution of a polyethylene glycol having a mean molecular weight in the range from 600 to 8,000 g/mole; (ii) adding an aqueous, possibly buffered solution... Agent: Powell Goldstein LLP

20080032942 - Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating BACE gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded... Agent: Mcdonnell, Boehnen, Hulbert And Berghoff, LLP

20080032949 - Embedded biocide: A phosphonium compound embedded in a matrix substrate wherein the phosphonium compound is selected from a group consisting of tris (hydroxyorgano) phosphine (THP), a THP+ salt (tetrakis (hydroxyorgano) phosphonium salt) or a condensate of THP and a nitrogen containing compound. The compound may be used to reduce the numbers of... Agent: Jean-louis Seugnet Rhodia

20080032919 - Bmp-7 variant compositions, methods and uses: Human Bone Morphogenic Protein 7 (hBMP-7) variant peptide chains, nucleic acids encoding these peptide chains, and methods of making and using the foregoing are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20080032917 - Flavivirus protease substrates and inhibitors: The invention provides substrate specificity profiles for flaviviral proteases (e.g., dengue proteases or West Nile protease). Optimal flaviviral protease substrate sequences, both to the prime side and non-prime side of the flaviviral protease recognition site, are disclosed herein. The flaviviral protease substrate sequences are used in designing substrates, inhibitors, and... Agent: Genomics Institute Of The Novartis Research Foundation

20080032921 - Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions: The present invention provides polynucleotides and polypeptides capable of enhancing the immune response of a human in need of protection against influenza virus infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an influenza protein... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20080032920 - Macromolecules modified with electrophilic groups and methods of making and using thereof: Described herein are macromolecules modified with electrophilic groups and methods of making and using thereof. The preparation of a thiol-reactive, electrophililic derivative of HA in order to prepare “crosslinker-free” hydrogels are described as well as compounds and methods that are capable of coupling two or more molecules, such as macromolecules,... Agent: Heller Ehrman LLP

20080032918 - Mast cell-derived renin: The invention relates to the discovery that renin is present in mast cells and can act in a localized manner to initiate and/or exacerbate a number of conditions. Thus, the invention provides methods for treating cardiac, vascular, lung, liver, cervical, intestinal, muscle, pancreatic, brain, kidney, skin and other conditions that... Agent: Schwegman, Lundberg & Woessner, P.A.

20080032916 - Preparation for use of aspartate and vitamin b12 or biotin for regulating ketone bodies: The invention relates to the use of specific protein and/or peptide fractions having a high aspartate content for regulating plasma glucose concentrations and increasing insulin sensitivity in a mammal. It has been found that high amounts of aspartate equivalents, especially in relative absence of glutamate equivalents, increase the glucose uptake... Agent: Foley And Lardner LLP Suite 500

20080032922 - Methods and means for producing proteins with predetermined post-translational modifications: Described are methods for identifying, selecting, and obtaining mammalian cells capable of producing proteinaceous molecules having predetermined post-translational modifications, wherein the post-translational modifications are brought about by the mammalian cell in which the proteinaceous molecule is expressed. Preferably, the predetermined post-translational modifications include glycosylation. Also described are methods for obtaining... Agent: Trask Britt

20080032923 - Effective use method of medicaments and method of preventing expression of side effect: A medicine which effectively functions as an immunosuppressant or anti-inflammatory agent and is effective in diminishing the occurrence of side effects. The medicine comprises a combination of: a diaryl sulfide or diaryl ether compound having a 2-amino-1,3-propanediol structure and having the function of diminishing lymphocytes circulating through the periphery; and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080032930 - Activatable clostridial toxins: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.... Agent: Dean G. Stathakis Allergan, Inc. -t2-7h

20080032931 - Activatable clostridial toxins: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.... Agent: Dean G. Stathakis Allergan, Inc. -t2-7h

20080032926 - Knockout non-human animal: The present invention relates to a knockout non-human animal whose genome comprises a disruption in at least one allele of the PHF3 gene, useful in developing drugs for diseases with the onset of atopic dermatitis or the like; a totipotent cell such as an ES cell which is essential to... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080032925 - Method for modulating inflammatory responses by altering plasma lipid levels: A method for treating an immune-related disorder in a patient comprising administering an agent to the patient for altering the patient's plasma concentration of free cholesterol, wherein said agent is a non-statin agent and is administered in an amount sufficient to modulate the immune-related disorder.... Agent: Synnestvedt Lechner & Woodbridge LLP

20080032932 - Method of reducing mortality and morbidity associated with critical illnesses: This invention relates to the use of glucagon-like peptide (GLP-1) compound to reduce the mortality and morbidity associated with critical illnesses wherein a patient is predisposed to or suffers from some type of respiratory distress.... Agent: Eli Lilly & Company

20080032929 - N-terminal truncation of cardiac troponin subunits and their roles in cardiovascular disease: The invention provides methods for diagnosing, preventing, treating, determining the likelihood of developing, or ameliorating a symptom associated with, cardiac disease by administering a therapeutically effective amount of a modulator, such as an inducer, of the posttranslational production of N-terminally truncated forms of cardiac troponin T. An exemplary modulator in... Agent: Marshall, Gerstein & Borun LLP

20080032927 - Treatment of development-related disorders: Disclosed are composition and methods for treating development-related disorders. Also disclosed are diagnosis methods, prognosis methods, and drug screening methods.... Agent: Fish & Richardson PC

20080032928 - Treatment of mucus hypersecretion: The present invention relates to treatment of mucus hypersecretion, to compositions therfor and manufacture of those compositions. The present invention relates particularly, though not exclusively, to the treatment of chronic bronchitis in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD.... Agent: Merchant & Gould PC

20080032933 - Type v phosphodiesterase inhibitors and natriuretic polypeptides: This document provides methods and materials related to PDE V inhibitors, natriuretic polypeptides, and combinations thereof. For example, compositions containing one or more PDE V inhibitors in combination with one or more natriuretic polypeptides are provided herein. In addition, methods for using PDE V inhibitors, natriuretic polypeptides, and combinations thereof... Agent: Fish & Richardson P.C.

20080032934 - Compositions for prevention of adhesions and other barrier applications: A method has been developed of preventing or limiting formation of adhesions by administering to a site in need thereof, in the absence of or after bleeding or leakage of fluid has been substantially stopped, a self-assembling material which forms a barrier to formation of adhesions. In one embodiment, the... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080032935 - Application of initial doses of lhrh analogues and maintenance doses of lhrh antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits: LHRH analogues and LHRH antagonists for use in the treatment or prophylaxis of hormone-dependent cancers, in particular prostate cancer, prostate carcinoma and/or advanced prostate carcinoma, by administering an initial dose of an LHRH analogue over a first period sufficient to effect hormonal castration, then administering a maintenance dose of an... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080032937 - Bioavailability and improved delivery of alkaline pharmaceutical drugs: Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition. The compositions include a molecular complex formed between an alkaline pharmaceutical drug and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or... Agent: Goodwin Procter LLP

20080032939 - Iridoid-saccharide compound and method of using same: A method for treatment of hyperproliferative tissue which by exposing the hyperproliferative tissue to a sufficient quantity of a purified iridoid compound to inhibit its growth, where the iridoid compound includes a polysubstituted cyclopenta(c)dihydropyran where the cyclopenta ring is substituted at its 2′ position with a ketofuryl group, where the... Agent: Michael L. Dunn

20080032940 - Methods for reducing anthracycline-induced toxicity: Methods for treating cancers/tumors, including administering to a subject an effective amount of a mitochondria-targeted antioxidant alone or in combination with a chemotherapeutic agents. Likewise, methods for mitigating toxicity associated with a chemotherapeutic agent including administering an effective amount of a mitochondria-targeted antioxidant with a single or with multiple chemotherapeutic... Agent: Quarles & Brady LLP

20080032945 - 2'-modified oligonucleotides: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the... Agent: Woodcock Washburn LLP

20080032943 - Method for detecting cancer and a method for suppressing cancer: An object of the invention is to find a cancer-associated gene to be used as an index for detecting canceration of cells and degree of malignancy of cancer, so as to to provide a method for detecting cancer using the cancer-associated gene as an index and provide a method of... Agent: Birch Stewart Kolasch & Birch

20080032941 - Method for rendering a system immunologically compatible utilizing a nucleic acid construct, a nucleic acid construct for inhibiting or regulating the function of an immune response (ir) gene and an immunologically compatible system containing a nucleic a: This invention provides a method for preparing an immunologically compatible system, e.g., organism, organ, tissue, or cells by appropriate genetic intervention which can take the form of introducing into the cells of such a system, a nucleic acid construct which, when present in a cell, inhibits or regulates the function... Agent: Enzo Biochem, Inc.

20080032947 - Pka ligands and polynucleotides encoding pka ligands: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate PKA activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal, epitope... Agent: Sughrue Mion, PLLC

20080032944 - Target nucleic acid of retrovirus integration: A nucleic acid that is a target of retrovirus integration and has a substantially palindromic sequence that includes a motif sequence: 5′-α1-α2- . . . -αn-X-βn- . . . -β2-β1-3′, wherein α1 to αn each represent a sequence consisting of contiguous 4 to 7 bases in 5′-CACAGTG-3′ or 5′-CACTGTG-3′, X... Agent: Osha Liang L.L.P.

20080032948 - Novel antifolate combination therapies: A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.... Agent: Eli Lilly & Company

20080032950 - Neurologically-active compounds: wherein R is methyl, ethyl, propyl, isopropyl, butyl, pentyl, neo-pentyl or cyclohexyl, or a salt or solvate thereof. These compounds are selective GABAC receptor antagonists. The invention also provides pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt or solvate thereof. The invention also provides methods... Agent: Welsh & Katz, Ltd

20080032951 - Ophthalmic compositions for treating ocular hypertension: This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective... Agent: Merck And Co., Inc

20080032952 - Combination therapies employing nicotinic acid derivatives or fibric acid derivatives: The present invention provides pharmaceutical compositions comprising a nicotinic acid derivative or a fibric acid derivative and a pyridoxal-5′-phosphate or a pyridoxal-5′-phosphate related compound and methods for using pharmaceutical compositions for reducing the risk of cardiovascular and other diseases.... Agent: Merchant & Gould PC

20080032953 - Method for inhibiting prebiotic effect of food proteins: The invention concerns a method for inhibiting prebiotic effect of food proteins on the oral bacteria microflora of carnivorous domestic animals, said method consisting in administering to the carnivorous domestic animal an inhibitor of said prebiotic effect, said inhibitor comprising a water-soluble food phosphate. The inhibitor may be administered alone... Agent: Ip Group Of Dla Piper US LLP

20080032954 - Vascular damaging agents for administration as an intravenous infusion: The invention concerns the use of a vascular damaging agent or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for administration as an intravenous infusion to a warm-blooded animal such as a human over a time period of more than 1 hour for use in the production... Agent: Ladas & Parry

20080032956 - 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds: Biologically active 19-nor vitamin D analogs substituted at C-2 in the A-ring with an ethylidene or an ethyl group. These compounds have preferential activity on mobilizing calcium from bone and either high or normal intestinal calcium transport activity which allows their in vivo administration for the treatment of metabolic bone... Agent: Andrus, Sceales, Starke & Sawall, LLP

20080032957 - Cytotropic heterogeneous molecular lipids (chml), method of preparation, and methods of treating patients with multiple cancers: Cytotropic Heterogeneous Molecular Lipids (CHML) are used to treat patients with multiple cancers. Numerous studies have been conducted in cellular, animal, pre-clinical and clinical trials. Results showed that CHML, as a biological molecular missile, can easily penetrate through the target cancerous cells to perform programmed cancer cell death (cancer apoptosis).... Agent: Birch Stewart Kolasch & Birch

20080032955 - Vitamin d3 analogues for the prevention and treatment of bone disorders: Novel vitamin D analogues are useful for making pharmaceutical compositions for the prevention or treatment of bone disorders such as osteoporosis... Agent: Clark & Elbing LLP

20080032958 - Withanolide compounds as inhibitors of fibrosis and identification of molecular targets for anti-fibrotic drug development: Provided are methods for screening for drugs effective for treating fibrotic conditions. One screening method comprises exposing a cell to a test compound, monitoring the effect of the test compound on the amount or form of a cell molecule, comparing the amount or form of the cell molecule with the... Agent: Buchanan, Ingersoll & Rooney PC

20080032959 - Estrogen receptor modulators: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone... Agent: Merck And Co., Inc

20080032960 - Pi3 kinase antagonists: The present invention provides novel PI3-Kinase antagonists and methods of use thereof.... Agent: Paul, Hastings, Janofsky & Walker LLP

20080032961 - Therapy employing lxralpha modolators: The invention also relates to the use of active modulators of LXRα activity or expression in stimulation of pre-adipocyte differentiation and hence also in the treatment of insulin resistance syndrome, or dyslipidemia, or type 2 diabetes.... Agent: White & Case LLP Patent Department

20080032962 - Stabilized freeze-dried formulation for cephalosporin derivatives: The present invention relates to a freeze-dried formulation for cephalosporin derivatives having increased stability, a solution for obtaining and a method for preparing such a formulation, as well as the use of certain compounds for stabilizing cephalosporin derivatives in freeze-dried formulations. The compounds preferably used as stabilizers according to the... Agent: Gibbons P.C.

20080032964 - Process for the synthesis of azetidinone: Provided are intermediates useful for the synthesis of hydroxyl-alkyl substituted azetidinones, processes of their preparation, and processes for the synthesis of certain hydroxyl-alkyl substituted azetidinones. Also provided are processes for the synthesis of 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone, or ezetimibe.... Agent: Kenyon & Kenyon LLP

20080032963 - Aminopyrimidines useful as kinase inhibitors: The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080032965 - Method for enhancing cognitive function: Pharmaceutical compositions and compositions are provided for treating cognitive disorders using synergistically effective amounts of 5-HT1A receptor antagonists and cognition enhancers.... Agent: Wilmerhale/wyeth

20080032967 - 1,4-disubstituted naphthalenes as inhibitors of p38 map kinase: In general, the present invention relates to compounds capable of inhibiting P38, methods for inhibiting P38 in vivo or in vitro, diagnostics for determining activity in the treatment of P38 and/or cytokine-associated conditions and methods for treating conditions associated with P38 activity or cytokine activity.... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20080032966 - Small molecule inhibitors of mrp1 and other multidrug transporters: A method of potentiating the activity of a therapeutic drug, like a chemotherapeutic drug or an antibiotic, in a cell or tissue, by inhibiting the efflux capability of a multidrug transporter are disclosed. The method is useful in the treatment of a cancer by sensitizing tumor cells to a chemotherapeutic... Agent: Marshall, Gerstein & Borun LLP

20080032968 - New compounds: m

20080032969 - Novel compounds: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.... Agent: Glaxosmithkline

20080032973 - 2-quinazolinone compounds and methods of use: wherein A1, A2, B, s, T, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use such as treatment of kinase mediated diseases by administering the compounds of Formula I or compositions including the compounds... Agent: Amgen Inc.

20080032971 - 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders: e

20080032970 - Amide derivatives of 7-amino-3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents: The present invention relates to novel amide derivatives of 7-amino-3-phenyl dihydropyrimido[4,5-d]pyrimidinones, to a process for their manufacture, medicaments containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents. The present derivatives are new compounds of the general formula (I).... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080032972 - Pyridopyrazines and derivatives thereof as alk and c-met inhibitors: e

20080032974 - Compounds and therapeutical use thereof: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20080032975 - Substituted fused pyrroleoximes and fused pyrazoleoximes: and the pharmaceutically acceptable salts thereof wherein R, Ar, A, n, R1 and R2 are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080032976 - 1h-indole-6-yl-piperazin-1-yl-methanone derivatives: d

20080032977 - Alkyne-substituted pyridone compounds and methods of use:

20080032979 - Omega-carboxyaryl substituted diphenyl ureas as raf kinease inhibitors: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.... Agent: Millen, White, Zelano & Branigan, P.C.

20080032978 - Soluble epoxide hydrolase inhibitors: Disclosed are urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory,... Agent: Foley & Lardner LLP

20080032980 - Mitotic kinesin inhibitors: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20080032981 - Aryl n-cyanoguanidines and methods related thereto: e

20080032982 - Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof: Compounds of the formula (I): in which R, R1 and R2 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and . processes for the preparation of these compounds. Compounds of formula (I) are activators of PPARα and... Agent: Millen, White, Zelano & Branigan, P.C.

20080032983 - Ortho-substituted n'-benzylidene-(3-hydroxyphenyl)acethydrazides: Novel ortho-substituted N′-benzylidene-(3-hydroxyphenyl)acetohydrazides of the formula (I), in which R1-R9 have the meanings indicated in Claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in... Agent: Millen, White, Zelano & Branigan, P.C.

20080032984 - Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use: v

20080032985 - 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them:

20080032986 - Benzyl amines, a process for their production and their use as anti-inflammatory agents:

20080032987 - Quercetin-containing compositions: This invention relates to a composition containing quercetin, vitamin B3, vitamin C, and folic acid. Also disclosed is a method of using the composition for enhancing physical or mental performance or treating various diseases or disorders.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080032988 - Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use: wherein A1, A2, B, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes... Agent: Amgen Inc.

20080032990 - Inhibitors of advanced glycation end products: e

20080032989 - Method of treating inflammatory diseases using tyroskine kinase inhibitors: Methods for treating and preventing inflammatory diseases using tyrosine kinase inhibitors are described. The inhibitors inhibit, e.g., T lymphocyte and/or B lymphocyte function, fibroblast proliferation, mast cells activation, and/or monocyte differentiation.... Agent: Perkins Coie LLP

20080032991 - 2, 8-disubstituted naphthyridine derivatives: and pharmaceutically acceptable salts thereof, wherein R1, R2, R2′, R3, R21, A1, A2, X, and Z are as defined herein. Compounds of formula A are useful in the treatment of diseases and/or conditions related to cell differentiation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080032992 - New pyridine analogues v: d

20080032993 - Substituted heterocyclic compounds:

20080032994 - Modified azole compounds as antifungal and antibacterial agents:

20080032995 - Aldh-2 inhibitors in the treatment of drug addiction:

20080032996 - Substituted quinazoline or pyridopyrimidine derivative:

20080032997 - Novel hydantoin derivatives as metalloproteinase inhibitors: The invention provides compounds of formula (I): wherein R1, R2, A, A1 and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.... Agent: Fish & Richardson P.C.

20080032998 - Pyrazolopyrimidines, a process for their preparation and their use as medicine: e

20080032999 - Prodrugs of 5-amino-3-(3'-deoxy-b-d-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione: The invention is directed to 5-amino-3-(3′-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione prodrugs, whose metabolized parent compound has immunomodulatory activity. The invention also relates to the therapeutic use of such prodrugs and pharmaceutical compositions thereof in treating disease states associated with abnormal cell growth, such as cancer.... Agent: Connolly Bove Lodge & Hutz LLP

20080033000 - Identification of cdki pathway inhibitors: The invention relates to the inhibition of the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.... Agent: Keown & Zucchero, LLP

20080033001 - Derivatives of variolin b: The invention provides antitumour compounds of formula (I), wherein R1 is an aromatic substituent; R2 is hydrogen or a substituent when the dotted line is absent, or R2 is absent when the dotted line represents a bond to give a double bond between the nitrogen which bears R2 and the... Agent: Fish & Richardson PC

20080033002 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Jonathan P. O'brien

20080033003 - Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents: in which the R1 group is as defined in the specification and includes the condensation of the camptothecin molecule in position 7 with a cyclopeptide containing the RGD sequence. Said compounds are endowed both with high affinity for integrin receptors αvβ3 and αvβ5 and with selective cytotoxic activity on human... Agent: Nixon & Vanderhye, PC

20080033004 - Synthesis of grossularines-1 and analogs thereof and method of use: In one embodiment of the present invention, a synthesis of grossularine-1 and N,N-didesmethylgrossularine-1 2 and analogs thereof based on a novel oxidative dimerization-electrocyclization sequence of 2-amino-4-(3-indolyl)imidazoles derived from oxotryptamine 3 is described.... Agent: Perkins Coie LLP

20080033005 - Methods for the treatment of multiple sclerosis: Certain compounds, including 5,6-dihydro-3,9-dihydroxyindolo[2,1-a-isoquinolin12yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone and arzoxifen, are useful for providing protection to oligodendrocytes and neurons of multiple sclerosis patients.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080033006 - Methods for the treatment of multiple sclerosis: r

20080033008 - Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof: A composition for treating, controlling, reducing, ameliorating, or alleviating infections and their inflammatory sequelae comprises a dissociated glucocorticoid receptor agonist (“DIGRA”) and an anti-infective agent, such as an antibacterial, antiviral, antifungal, antiprotozoal agent, or a combination thereof. The composition can be formulated for topical application, injection, or implantation.... Agent: Bausch & Lomb Incorporated

20080033007 - Substituted tetrahydroisoquinoline compounds for cancer therapy: Disclosed are compounds that are effective for selectively killing cancer cells. Compounds have been demonstrated to be especially effective for killing glioma cells, while exhibiting low toxicity to normal cells.... Agent: Donna J. Russell

20080033010 - Combination therapy of erdosteine and beta-2 agonists for treating respiratory pathologies characterized by non reversible or partially reversible airway obstruction: The invention relates to a method for improving the reversibility of bronchial obstruction in a subject affected by chronic obstructive pulmonary disease comprising the administration to said subject of erdosteine in combination with a beta agonist.... Agent: Ladas & Parry

20080033009 - Solid pharmaceutical formulation: This invention provides a solid pharmaceutical formulation having high physical strength and further having excellent drug release properties and digestibility of excipients when administered, which comprises (a) an active medical ingredient and (b) a pre-gelatinized starch in an amount of 10 to 90% by weight, said pre-gelatinized starch being prepared... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080033011 - Novel benzo[d][1,3]-dioxol derivatives: The present invention relates to an isotopologue of paroxetine substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to paroxetine. They may also be used to accurately determine the concentration... Agent: Edwards Angell Palmer & Dodge LLP

20080033013 - Pyrazolylphenyl and pyrrolylphenyl inhibitors of lta4h for treating inflammation: In these compounds ring (a) is a pyrazole or pyrrole; Q is selected from the group consisting of a direct bond, O, S, SO, SO2, NR1, CH2, CF2, and C(O); HET is a 4-7-membered saturated nitrogenous heterocycle; and taken together ZW is H or Z is (CH2)1-10 in which one... Agent: Heslin Rothenberg Farley & Mesiti PC

20080033012 - Enzyme inhibitors: where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease... Agent: Fish & Richardson PC

20080033014 - Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin reuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor: A subject-matter of the present invention is pharmaceutical compositions comprising, in combination, at least one active ingredient chosen from (S)-(−)-N-[4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide and pharmaceutically acceptable salts there and at least one second active ingredient chosen from selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors and pharmaceutically acceptable salts thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080033015 - Histone deacetylase inhibitors: This invention relates to hydroxamic acid derivatives having a urea linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases, and... Agent: Merck And Co., Inc

20080033016 - Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them: in which A, X, R(1), R(2) and R(3) have the meanings indicated in the claims. The compounds of formula I are valuable active pharmaceutical ingredients which show in particular an inhibiting effect on ATP-sensitive potassium channels of the cardiac muscle and are suitable, for example, for the treatment of disorders... Agent: Ronald G. Ort Sanofi-aventis U.s. LLC

20080033017 - Compositions for enhanced acaricidal activity: A composition for control of parasitic insects and acarids, comprising a combination of pyrethroids and chloronicotinyl compounds.... Agent: Bayer Healthcare LLC

20080033018 - Therapeutic agents for overactive bladder: The present invention provides a therapeutic agent for overactive bladder, which has both a KATP channel opening action and a nitrate-like action and is further expected to produce an ameliorating effect for ensuring a reflexive and suitable cooperation between contraction-relaxation of abdominal/bladder wall muscle and relaxation-contraction movement of urethral sphincter... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080033019 - Cholesterol lowering drug combination: A patient with dyslipidemia is treated with a cholesterol blood level lowering effective amount of a non-statin cholesterol lowering agent and an amount of nitric oxide (NO) donating compound effective to mediate increase in nitric oxide bioactivity in blood.... Agent: Bacon & Thomas, PLLC

20080033020 - 3-pyridinylethylbenzamide derivatives as fungicides: p

20080033021 - Wash composition for the handling of contact lenses: A method for minimizing microbial contamination of contact lenses during the handling of the lenses. The method comprises instructing a person that wears contact lenses to wash their hands prior to the handling of the contact lenses with a wash composition. The wash composition includes one or more surfactants selected... Agent: Bausch & Lomb Incorporated

20080033022 - Inhibitors of c-jun n-terminal kinases (jnk): The present invention relates to inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions... Agent: Vertex Pharmaceuticals Inc.

20080033024 - Aryl amino acid derivatives as inhibitors for treating inflammation: e

20080033023 - Therapeutic compounds:

20080033025 - Inhibition of lethal factor protease activity from anthrax toxin: The present invention provides compounds that efficiently and specifically inhibit lethal factor (LF) protease activity of anthrax toxin.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080033026 - Antimicrobial compositions, methods and systems: The invention provides methods for treating a surface, the method including steps of applying a surface treatment composition to a surface, wherein the surface treatment composition includes a substantially phenol-free cleansing agent and an antimicrobial agent, the antimicrobial agent comprising 9-decenoic acid, a salt of 9-decenoic acid, an ester of... Agent: Kagan Binder, PLLC

20080033027 - Drug combination pharmaceutical compositions and methods for using them: The invention provides preparations, formulations, kits and other products of manufacture (e.g., blister packs) comprising combinations of beneficial ingredients that are serviceable as therapies for improving states and disease symptoms such as involving inflammation, excessive sympathoneural drive, cachexia, anorexia, and anorexia-cachexia, as well as stress or anxiety related thereto, and... Agent: Immune Nutraceuticals, Inc. C/o Mofo S.d.

20080033028 - Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment: Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.... Agent: Merck And Co., Inc

20080033029 - Treating digestive tract conditions: This document involves methods and materials related to increasing the number of interstitial cells of Cajal and treating digestive tract conditions.... Agent: Fish & Richardson P.C.

20080033030 - Fluvastatin sodium pharmaceutical compositions: Various fluvastatin compositions and methods for preparing them are described. One example is a controlled release pharmaceutical composition comprising fluvastatin and at least one non-ionic hydrophilic polymer, wherein the composition is substantially free of hydroxypropyl methylcellulose. Another example is a stable pharmaceutical composition comprising fluvastatin, preferably, fluvastatin sodium wherein the... Agent: Kenyon & Kenyon LLP

20080033031 - Antibiotic compounds, compositions and methods of treatment: Antibiotic compounds and compositions and methods for the treatment of dermatological conditions including a sulfoxide or sulfone derivative of an antibiotic from the lincomycin family of antibiotics, or pharmaceutically acceptable salts thereof, optionally including a peroxide component.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080033032 - Novel polymorphs of the potassium salt of atorvastatin: Novel polymorphs Forms I, II and III of the potassium salt of Atorvastatin, (βR,δR)-2-(p-fluorophenyl)-β, δ-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid, are obtained directly by precipitation of the potassium salt of Atorvastatin with ethanol (polymorph I), with 1-propanol (polymorph II) and by recrystallisation of polymorph I from 2-propanol (polymorph III).... Agent: Nath & Associates

20080033033 - 8-azaprostaglandin derivatives and medical use thereof: (wherein, all the symbols have the same meanings as that of the specification.) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and/or treatment of immunological diseases,... Agent: Sughrue-265550

20080033034 - Phenylalkyl n-hydroxyureas for combating atherosclerotic plaque: The method of treating patients be administering phenylalkyl N-hydroxurea derivatives for combating atherosclerotic plaque and cardiovascular diseases and compositions for this use.... Agent: Gibbons P.C.

20080033035 - Antiproliferative activity of the leiodermatolide class of macrolides: The subject invention provides novel biologically active compounds that have utility for use in inhibiting cellular proliferation. Pharmaceutical compositions comprising these compounds are also provided. In a specific embodiment, the compounds and compositions of the subject invention can be used in the treatment of cancer.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080033036 - Composition and method for promoting hair growth: The present invention provides a method and composition for promoting hair growth in a mammal which comprises a prostaglandin compound having two hetero atoms at the 15 position as an active ingredient thereof.... Agent: Sughrue Mion, PLLC

20080033037 - Utilisation de la silymarine et/ou de ses constituants comme agents promoteur de la pigmentation de la peau ou des cheveux: The present invention relates to the use of silymarin, or of the main constituents thereof alone or as a mixture, chosen from silybin (or 2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-6-(3,5,7-trihydroxy-4-oxobenzopyran-2-yl)benzodioxine), isosilybin, silydianin, silychristin, silandrin, silymonin and taxifolin, isolated enantiomers thereof and also salts thereof, for the manufacture of compositions for inducing, restoring or stimulating pigmentation... Agent: Oliff & Berridge, PLC

20080033038 - Compositions of polyphenols and methods of use: The subject invention concerns materials and methods for treating or preventing any condition or disease that is treatable by a green tea polyphenol, or an analog, isomer, metabolite, or prodrug thereof, wherein the polyphenol is administered as an intranasal formulation to a person or animal in need of treatment. In... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080033039 - Combination of ceramide and oxaliplatin for inducing cell death and uses thereof in treating cancer: This invention provides a method for increasing apoptosis in a cancer cell comprising contacting the cancer cell with (a) oxaliplatin and (b) C6-ceramide, sequentially or concomitantly, wherein the oxaliplatin and C6-ceramide are in amounts such that the apoptosis induced by the combination of oxaliplatin and C6-ceramide is greater than the... Agent: Cooper & Dunham, LLP

20080033040 - Methods and compositions for screening involving endothelial cells under shearing conditions: The present invention concerns screening methods and compositions relating to endothelial cell function. More specifically, it provides screening methods to identify or characterize pathways and factors involved in endothelial cell function by employing conditions that simulate physiological stress. Additional methods can be implemented to identify candidate drugs for the treatment... Agent: Fulbright & Jaworski L.L.P.

20080033041 - Use of phenylethanolaminotetralines for preparing anxiolytic drugs: e

20080033042 - Urea-and urethane-substituted acylureas, process for their preparation and their use:

20080033043 - Modified release formulations of a bupropion salt: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080033044 - Modified release formulations of a bupropion salt: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080033045 - Treatment of psychiatric disorders: The invention relates to the treatment of psychiatric disorders.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20080033047 - Combination/association of adapalene and benzoyl peroxide for treating acne lesions: Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).... Agent: Buchanan, Ingersoll & Rooney PC

20080033046 - Treatment of myocardial infarction with 11hsd1 inhibitors: The present invention relates to a method for the treatment of myocardial infarction. In particular the invention relates to the treatment of myocardial infarction using inhibitors of a particular enzyme involved in glucocorticoid metabolism.... Agent: Edwards Angell Palmer & Dodge LLP

20080033048 - Piggyback bifunctional vasodilators: The present invention generally relates to at least one bifunctional vasodilator composition, and methods for making and using the same. Some embodiments may relate to functionalizing, with nitric oxide, a vasodilator having a secondary amine, thereby forming a diazeniumdiolate derivative of the vasodilator. Such embodiments may be capable of decomposing... Agent: Roetzel And Andress

20080033049 - Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents: e

20080033050 - Method of treating thermoregulatory disfunction with paroxetine: The present invention relates to a method for treating a patient suffering from a thermoregulatory dysfunction, especially hot flashes and flushes associated with hormonal changes due to naturally occurring menopause (whether male or female) or due to chemically or surgically induced menopause. The method is also applicable to treating the... Agent: Irving M. Fishman Cohen Tauber Spievack & Wagner

20080033051 - Crystal forms of o-desmethylvenlafaxine: Methods for preparing crystalline forms of O-desmethylvenlafaxine are described.... Agent: Kenyon & Kenyon LLP

20080033052 - Dermal anesthetic compounds: The present invention relates to new tetralin compounds, the methods of preparing said tetralin compounds, the method of using said tetralin compounds as local anesthetics and dermal anesthetics, said compounds having particularly valuable properties as dermal and topical anesthetics in mammals, including man, as well as compositions containing said compounds.... Agent: Nields & Lemack

20080033053 - Cross-reference to related applications: Adamantane and other agents with similar effects on gene expression are useful in the treatment or prevention of ocular disorders.... Agent: Hoffman Warnick & D'alessandro, LLC

20080033054 - Process for preparing memantine hydrochloride substantially free of impurities: The present invention encompasses processes for preparing Memantine hydrochloride and its derivatives, substantially free of impurities.... Agent: Kenyon & Kenyon LLP

20080033055 - method for the synthesis of curcumin analogues: The present invention relates to improved methods for achieving the synthesis of 1,7-diaryl-1,6-heptadiene-3,5-diones, and in particular curcumin and its analogues. The invention provides a process for synthesizing such compounds in substantial yield and purity using environmentally benign processes and materials. The invention also relates to the use of such synthesized... Agent: Edell, Shapiro & Finnan, LLC

20080033056 - Xanthohumol based protein kinase modulation cancer treatment: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, commonly found in hops.... Agent: Mcdermott Will & Emery LLP

20080033057 - Hexahydro-isoalpha acid based protein kinase modulation cancer treatment: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on hexahydro-isoalpha acids, commonly found in hops.... Agent: Mcdermott Will & Emery LLP

20080033058 - Personal care compositions that deposit hydrophilic benefit agents: A personal care composition comprising a hydrophilic benefit active, a multi-wetting material, and an aqueous phase, wherein the hydrophilic benefit active may be a hydrophilic solid or a hydrophilic liquid with a structurant, wherein the multi-wetting material and the hydrophilic benefit active form a multi-wetting phase. These compositions provide improved... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080033059 - Enteric coating compositions: This invention is in the field of enteric film coating, dry powder compositions for coating pharmaceutical dosage forms. It relates to aqueous enteric coating and provides a dry enteric film coat composition based on an acrylate copolymer and other excipients, but without an alkalinizing agent in the composition.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080033060 - Use of a compound modulating at least one receiver selected in a group comprising an interleukin 8 type b receptor and pacap-1 receptor for porparing a pharmaceutical composition for rosacea treatment: The invention relates to the use of a modulator of at least one receptor chosen from the group comprising the IL-8RB receptor and the PAC-1 receptor for the preparation of a pharmaceutical composition for treating rosacea.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080033061 - Cation conducting gabaa receptors and their use: This invention relates to cation conducting GABAA receptors, mutated GABAA receptor subunits, polynucleotide sequences encoding mutated subunits, expression vectors comprising the mutated subunits, host cells capable of expressing the mutated subunits, drug screening methods, and chemical substances identified by the drug screening methods of the invention.... Agent: Birch Stewart Kolasch & Birch

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140710: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 2.76355 seconds

PATENT INFO